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The AAAAI and the ACAAI have jointly accepted responsibility
for establishing ‘‘The Diagnosis and Management of
Anaphylaxis Practice Parameter: 2010 Update.’’ This is a
complete and comprehensive document at the current time. The
medical environment is a changing environment, and not all
recommendations will be appropriate for all patients. Because
this document incorporated the efforts of many participants, no
single individual, including those who served on the Joint Task
Force, is authorized to provide an official AAAAI or ACAAI
interpretation of these practice parameters. Any request for
information about or an interpretation of these practice
parameters by the AAAAI or ACAAI should be directed to the
Executive Offices of the AAAAI, the ACAAI, or the Joint
Council of Allergy, Asthma and Immunology. These parameters
are not designed for use by pharmaceutical companies in drug
promotion. (J Allergy Clin Immunol 2010;126:477-80.)
Key words: Anaphylaxis, drug allergy, latex allergy, food allergy,
exercise anaphylaxis, intraoperative anaphylaxis
To read the Practice Parameter in its entirety, please download
the online version of this article from www.jacionline.org. The full
document follows the Executive Summary.
EXECUTIVE SUMMARY
Evaluation and management of the patient with a
history of episodes of anaphylaxis
The history is the most important tool to determine whether a
patient has had anaphylaxis and the cause of the episode (C).
A thorough differential diagnosis should be considered, and other
conditions should be ruled out (C). Laboratory tests can be helpful
to confirm a diagnosis of anaphylaxis or rule out other causes.
Proper timing of such tests (eg, serum tryptase) is essential (B). In
the management of a patient with a previous episode of anaphy-
laxis, education is necessary. Emphasis on early treatment,
specifically the self-administration of epinephrine, is essential
477
Abbreviation used
NLR: Natural rubber latex
food ingestion or any meal, and exercise. (C) Patients with food
allergy should pay close attention to food advisory labeling
(eg, ‘‘may contain’’), which has become more prevalent. (C)
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vatructed to wear and/or carry identifi-). The pried matient can be ins
There are 3 groups at high risk of reaction to latex: health care
workers, childrenwith spina bifida and genitourinary abnormalities,
cation denoting the condition (eg,MedicAlert bracelet; MedicAl-
ert Foundation of the United States, Turlock, Calif) and can also
be instructed to have telephone numbers for paramedic rescue
squads and ambulance services on hand. A written action plan
can be helpful in this regard (C).
Office management of anaphylaxis
Anaphylaxis is an acute, life-threatening systemic reaction withechanisms, clinical presentations, and severity that results
from the sudden systemic release of mediators frommast cells and
basophils. (B) The more rapidly anaphylaxis develops, the more
likely the reaction is to be severe and potentially life-threatening.
(C) Prompt recognition of signs and symptoms of anaphylaxis is
crucial. If there is any doubt, it is generally better to administer
epinephrine. (C) Epinephrine and oxygen are the most important
therapeutic agents administered in anaphylaxis. Epinephrine is the
drug of choice, and the appropriate dose should be administered
promptly at the onset of apparent anaphylaxis. (C) Appropriate
volume replacement either with colloid or crystalloids and rapid
transport to thehospital are essential for patientswhoare unstable or
refractory to initial therapy for anaphylaxis in the office setting. (B)
Medical facilities should have an established plan of action to deal
with anaphylaxis that is regularly practiced and the appropriate
equipment to treat anaphylaxis. (B) Physicians and office staff
should maintain clinical proficiency in anaphylaxis management.
(D) In addition, telephone numbers for paramedical rescue squads
and ambulance services might be helpful to have on hand. (C)
SPECIFIC TRIGGERS/SETTING FOR ANAPHYLAXIS
Anaphylaxis to foods
Food is the most common cause of anaphylaxis in the outpatient
setting, and food allergens account for 30% of fatal cases of
anaphylaxis. (D) The most commonly implicated foods responsible
for food-induced anaphylaxis include peanuts, tree nuts, fish,
shellfish, cow’s milk, soy, and egg. In addition, sesame seed has
recently been identified as a significant cause of food-induced
anaphylaxis. (C) Common themes associated with fatal food
anaphylaxis include the following: reactions commonly involve
peanuts and tree nuts; cutaneous and respiratory symptoms are
frequently observed; victims are typically teenagers and young
adults; patients have a previous history of food allergy and asthma;
and there is a failure to administer epinephrine promptly. (C) As is
the case of anaphylaxis followingother agents, asthma is a risk factor
for more severe food-induced anaphylaxis. (C) Biphasic anaphylac-
tic reactions can occur in up to 25% of fatal and near-fatal food
reactions. (C) Serum tryptase measurements may not be elevated
in cases of food-induced anaphylaxis. (C)The rapid use of injectable
epinephrinehasbeenshown tobe effective in the initialmanagement
of food-induced anaphylaxis, but subsequent doses may be needed.
(C)Patientswhoexperience anaphylaxis shouldbe observed for lon-
ger periods if they have experienced food-induced anaphylaxis. (C)
Food-dependent, exercise-induced anaphylaxis is a unique clinical
syndrome inwhich anaphylaxisoccurswithin a fewhours of specificNatural rubber latex–induced anaphylaxisand workers with occupational exposure to latex. (C) In vitro assays
for IgE to natural rubber latex (NRL) are typically recommended as
a first step in evaluating latex sensitivity. However, because of their
suboptimal diagnostic predictive value, positive and negative results
must be interpreted on the basis of the history. If the test is positive
with a high clinical likelihood, latex sensitivity would be reasonable
to pursue. In contrast, if the test is negative with a high clinical like-
lihood, latex sensitivity still must be considered. (C) A standardized
commercial skin test reagent for NRL is not available in the United
States. Allergists have preparedNRL extracts from gloves to use for
clinical testing. It should be noted, however, that such extracts pre-
pared fromgloves demonstrate tremendous variability in the content
of NRL allergen. Nevertheless, skin prick tests with NRL extract to
identify IgE-mediated sensitivity should be considered if patients
are members of high-risk groups or have a clinical likelihood of
NRL allergy and have negative in vitro tests. (C) Patients with spina
bifida (regardless of a history of NRL allergy) and patients with a
positive history of NRL allergy ideally should have all medical-
surgical-dental procedures performed in a NRL-safe environment.
(D) A NRL-safe environment is an environment in which no NRL
gloves are used in the room or surgical suite and there are limited
NRL accessories (catheters, adhesives, tourniquets, and anesthesia
equipment or devices) that come in contact with the patient. (D)
In health care settings, general use ofNRLgloveswith negligible al-
lergen content, powder-free NRL gloves, and nonlatex gloves and
medical articles should be considered in an effort to minimize pa-
tient exposure to latex. Such an approach can minimize NRL sensi-
tization of health care workers and patients and reduce the risk of
reactions to NRL in previously sensitized individuals. (D) Patients
with a diagnosis of NRL allergy by history and/or skin testing can
wear amedical identification bracelet, carry amedical identification
card, or both. If patients have a history of anaphylaxis to NRL, it is
important for them to carry autoinjectable epinephrine. (D)
Anaphylaxis during general anesthesia, the
intraoperative period, and the postoperative period
The incidence of anaphylaxis during anesthesia has been
reported to range from 1 in 4000 to 1 in 25,000. Anaphylaxis
during anesthesia can present as cardiovascular collapse, airway
obstruction, and/or skin manifestation. (C) It can be difficult to
differentiate between immune and nonimmune mast cell–medi-
ated reactions and pharmacologic effects from the variety of
medications administered during general anesthesia. In addition,
cutaneous manifestations of anaphylaxis are less likely to be
apparent when anaphylaxis occurs in this setting. (B) The
evaluation of IgE-mediated reactions to medications used during
anesthesia can include skin testing to a variety of anesthetic
agents. (B) Specifically, thiopental allergy has been documented
by skin tests. (B) Neuromuscular blocking agents such as
succinylcholine can cause nonimmunologic histamine release,
but there have also been reports of IgE-mediated reactions in
some patients. (B) Reactions to opioid analgesics are usually
caused by direct mast cell mediator release rather than IgE-
dependent mechanisms. (B) Antibiotics that are administered
perioperatively can cause immunologic or nonimmunologic
reactions. (B) Protamine can cause severe systemic reactions
reproduce symptoms. (C) All patients with exercise-induced
anaphylaxis must be advised to stop exercising immediately at the
first sign of symptoms because continued exertion causes the
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Blood transfusions can elicit a variety of systemic reactions,
some of which might be IgE-mediated or mediated through other
immunologic mechanisms. (B) Methylmethacrylate (bone ce-
ment) has been associated with hypotension and various systemic
reactions, although no IgE mechanism has been documented. (C)
The management of anaphylactic reactions that occur during
general anesthesia is similar to the management of anaphylaxis in
other situations. (B)
Seminal fluid–induced anaphylaxis
Coital anaphylaxis caused by human seminal fluid has been
shown to be a result of IgE-mediated sensitization to seminal
plasma proteins of varying molecular weight. (C) Postcoital local
reactions to human seminal plasma are probably IgE-mediated on
the basis of the successful response to rapid seminal plasma
desensitization. (C) A history of atopic disease is the most
consistent risk factor for seminal fluid–induced anaphylaxis. (C)
The diagnosis of seminal plasma anaphylaxis may be confirmed
by skin testing with fresh whole human seminal plasma or its
fractions obtained from the male partner. It is essential to exclude
other underlying causes such as allergens in natural rubber latex
condoms or in drugs or foods passively transferred via seminal
plasma. (D) Greater than 90% of the allergenic proteins range
between 12 and 75 kd. Prostate-specific antigen has been dem-
onstrated to be a relevant allergen in some cases. (C) Systemic and
localized reactions to seminal plasma can be prevented by correct
use of condoms. Nevertheless, in the event of barrier failure,
sexual partners should be prepared to treat acute anaphylaxis. (C)
Subcutaneous immunotherapy to properly prepared fractions of
seminal plasma collected from male partners has been successful
in preventing anaphylaxis to seminal plasma. (C) Successful
intravaginal graded challenge with whole seminal plasma of the
male partner has been reported in a few cases, but the duration of
protection is unknown. This treatment approach is advocated
before pursuing desensitization using relevant seminal plasma
protein fractions. (C) Patients with seminal plasma allergymay be
able to conceive without undergoing desensitization, by artificial
insemination with washed spermatozoa. (C)
Exercise-induced anaphylaxis
Exercise-induced anaphylaxis is a heterogeneous form of
anaphylaxis in which exercise is the immediate trigger for the
development of symptoms. Typical symptoms include extreme
fatigue, warmth, flushing, pruritus, and urticaria, occasionally
progressing to angioedema, wheezing, upper airway obstruction,
and collapse. (A) The pathophysiologic events during exercise
that precipitate symptoms are not known, although promising
lines of research exist. (C) Some patients experience symptoms
only if other contributing factors or cotriggers are present in
association with exercise. These cotriggers include ingestion of
specific foods—or in some patients, ingestion of any food—
nonsteroidal anti-inflammatory drugs, and high pollen levels. (C)
The clinical history should focus on identification of these
possible cotriggers. Evaluation for sensitization to food allergens,
particularly grains and seafood, can be performed. The diagnosis
is usually made on the basis of the history and exclusion of other
disorders. Exercise challenge testing does not consistentlyattacks to worsen. In addition, all patients should carry epineph-
rine autoinjectors and exercise with a partner who can recognize
symptoms and administer epinephrine if necessary. (D) Prophy-
lactic medications are not effective for preventing attacks in the
majority of patients, although a small subset does appear to
benefit from daily administration of H1 antihistamines. (D) The
prognosis of patients with exercise-induced anaphylaxis is gen-
erally favorable, although at least 1 fatality has been reported.
Most patients experience fewer and less severe attacks over time.
It is unclear whether this is the result of trigger avoidance or a
change in the underlying condition. (C)
Idiopathic anaphylaxis
The symptoms of idiopathic anaphylaxis are identical to those
of episodes related to known causes. (C) Patients with idiopathic
anaphylaxis should receive an intensive evaluation, including a
meticulous history to rule out a definite cause of the events. (C)
There might be a need for specific laboratory studies to exclude
systemic disorders such as indolent systemic mastocytosis. This
might include a measurement of serum tryptase when the patient
is asymptomatic, measurement of total tryptase during or within 4
hours of an acute episode, and the ratio of mature (b) tryptase to
total tryptase during an episode. To exclude hereditary angioe-
dema or acquired C1 inhibitor deficiency, a C4 concentration can
be obtained because it will be reduced during or in the absence of
severe angioedema in those conditions but normal in idiopathic
anaphylaxis. (C) There might be a need for selective skin testing
for detection of antifood IgE antibodies when foods have been
ingestedwithin 2 hours of the onset of an episode. (C) Empiric use
of oral corticosteroids combined with H1 antagonists has been
demonstrated to reduce the frequency/severity of episodes. (C)
Patients with idiopathic anaphylaxis should carry epinephrine,
should know the indications for self-administration, and can carry
information denoting their condition. (C)
Anaphylaxis and allergen immunotherapy
There is a small risk of near-fatal and fatal anaphylactic
reactions to allergen immunotherapy. (C) Patients with asthma,
particularly if poorly controlled, are at higher risk for serious
potentially life-threatening anaphylaxis to allergen immunother-
apy injections. (C) There is concern that patients taking b-
adrenergic blocking agents may be at an increased risk of having a
systemic reaction to allergen immunotherapy injections that is
difficult to treat. (B) Allergen immunotherapy vaccines should be
administered only by health care professionals trained in the
recognition and treatment of anaphylaxis, only in health care
facilities with the proper equipment for the treatment of anaphy-
laxis, and in clinics with policies and procedures that minimize
the risk of anaphylaxis. (D)
Anaphylaxis to drugs and biological modifiers
Low-molecular-weight medications induce an IgE-mediated
reaction only after combining with a carrier protein to produce a
complete multivalent antigen. (B) Penicillin is the most common
cause of drug-induced anaphylaxis. (C) Penicillin spontaneously
degrades to major and minor antigenic determinants, both of
which should be included in skin testing for penicillin hypersen-
sitivity. (B) The negative predictive value of penicillin skin testing
with both major and minor determinants (for immediate-type
reactions) is between 97% and 99% (depending on the reagents
used), and the positive predictive value is at least 50%. (B) The
autoinjectable epinephrine, receive instruction in its proper use
and indications for use, and be advised to set up an appointment
with an allergist-immunologist. Patients should understand, how-
venom-induced and latex-induced anaphylaxis, and possibly
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losporins is unknown but appears to be low. Four percent of
patients proven to have penicillin allergy by means of penicillin
skin testing react to cephalosporin challenges. (C) Patients with a
history of penicillin allergy who have negative penicillin skin test
responses can safely receive cephalosporins. (B) Patients who
need to receive a cephalosporin and who have a history of
penicillin allergy and a positive penicillin skin test response can
(1) receive an alternate (non–b-lactam) antibiotic, (2) receive a
cephalosporin through graded challenge, or (3) receive a ceph-
alosporin through rapid desensitization. (C) Aztreonam does not
cross-react with other b-lactams, except ceftazidime, with which
it shares a common R-group side chain. (B) The degree of cross-
reactivity between penicillin and carbapenems appears to be low.
(C) Diagnosis of IgE-mediated reactions to non–b-lactam anti-
biotics is limited by a lack of knowledge of the relevant allergenic
determinants and/or metabolites. (C) Aspirin and nonsteroidal
anti-inflammatory drugs are the second most common cause of
drug-induced anaphylaxis. (C) Anaphylactic reactions to aspirin
and other nonsteroidal anti-inflammatory drugs appear to be
medication-specific. (D)
Anaphylactic reactions to omalizumab have occurred, and
postmarketing data indicate that there is an incidence of approx-
imately 0.2% in treated patients. These reactions have been
unusual in that they can be delayed in onset and progressive. (C)
On the basis of the fact that anaphylactic reactions to omalizumab
can be delayed, an observation period of 2 hours for the first 3
injections and 30 minutes for subsequent injections is indicated.
(D) All patients receiving omalizumab should be prescribed an
automatic epinephrine injector and instructed in its use. Physi-
cians should ensure that patients have such an injector with them
at the time of the visits to the office for injection. (D)
A preassessment (before the injection of omalizumab) of the
patient’s current health status should be made. This should
include vital signs, an assessment of asthma control, and a
measurement of lung function. (D)
Insect sting anaphylaxis
Anaphylaxis to insect stings has occurred in 3% of adults and1% of children who have been stung and can be fatal even on the
first reaction. (B) Cutaneous systemic reactions aremore common
in children, hypotensive shock is more common in adults, and
respiratory complaints occur equally in all age groups. (B) The
chance of a systemic reaction to a sting is low (5% to 10%) in
patients who have large local reactions and in children with mild
(cutaneous) systemic reactions. (A) Recurrence rates of reactions
in adults vary between 25% and 70% depending on the severity of
the previous systemic sting reaction. (A)
Venom skin tests are most accurate for diagnosis, but in vitro
testing is an important complementary test. (A) The degree of
sensitivity on skin or in vitro tests does not reliably predict the se-
verity of a sting reaction. (B) Because asymptomatic venom sen-
sitization can be detected in up to 25% of adults, diagnosis cannot
be made on skin testing alone; the history is essential. (C) Patients
discharged from emergency care for anaphylaxis should be givenever, that using autoinjectable epinephrine is not a substitute for
emergency medical attention. (A) Venom immunotherapy should
be recommended for patients with systemic sensitivity to stinging
insects because this treatment is highly (90% to 98%) effective.
(B) Most patients can discontinue venom immunotherapy after
5 years with low residual risk (<10%) of a severe sting reaction.
(A) There is a need to develop tests that are (1) markers of suscep-
tibility and can serve as screening tests to identify patients at high
risk of sting anaphylaxis, and (2) markers of tolerance induction
to identify patients who can safely discontinue venom immuno-
therapy. (D) In a retrospective study of patients experiencing an-
aphylaxis from hymenoptera venom, Angiotensin Converting
Enzyme (ACE) inhibitor exposure was associated with a statisti-
cally significant increase in risk for more severe anaphylaxis
(odds ratio, 5 2.27; 95% CI, 1.13-4.56; P 5 .019). For patients
who require an ACE inhibitor for an indication for which there
is no equally effective alternative available, a management deci-
sion by the physician prescribing venom immunotherapy should
be approached cautiously on an individualized risk-benefit basis.
Prevention of anaphylaxis
While atopy may be a risk factor for seminal fluid anaphylaxis,anaphylactic reactions to radiographic contrast material, it does
not appear to be a risk factor for anaphylactic reactions to
medications. (C) Avoidance management should be individual-
ized, taking into consideration factors such as age, activity,
occupation, hobbies, residential conditions, access to medical
care, and the patient’s level of personal anxiety. (C) Even in cases
in which the allergen is known, avoidance measures may not
always be successful. Therefore, patients should be instructed in
self-management of anaphylaxis. (C) When avoidance is inef-
fective or not possible, other approaches can be used. For
example, venom immunotherapy is successful in preventing
anaphylaxis in up to 98% of patients who have previously
experienced venom-induced anaphylaxis. (A) Pharmacologic
prophylaxis should be used in select situations, such as to prevent
recurrent anaphylactic reactions to radiographic contrast material
and fluorescein, as well as to prevent idiopathic anaphylaxis. In
these specific situations, prophylaxis with glucocorticosteroids
and antihistamines markedly reduces the occurrence of subse-
quent reactions. (C) Desensitization to medications that are
known to have caused anaphylaxis can be effective. The desen-
sitization is temporary, and if the medication is required in the
future, the desensitization process must be repeated. (C) Patient
education might be the most important preventive strategy.
Education can emphasize hidden allergens, cross-reactivity be-
tween various allergens and drugs, unforeseen risks during
medical procedures, and when and how to use self-administered
epinephrine. Physicians should educate patients about the risks of
future anaphylaxis as well as the benefits of avoidance measures.
(B) Patients at increased risk for anaphylactic events, such as
those with allergy to insect venom, should avoid drugs that might
increase their susceptibility and/or complicate themanagement of
an anaphylactic event. (C)
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These parameters were developed by the Joint Task Force on
Practice Parameters, representing the American Academy of
Anaphylaxis to foods
Latex-induced anaphylaxisAllergy, Asthma and Immunology; the American College Anaphylaxis during general anesthesia, the intraoperative
of Allergy, Asthma and Immunology; and the Joint Council
of Allergy, Asthma and Immunology.
The American Academy of Allergy, Asthma and Immunol-
ogy (AAAAI) and the American College of Allergy, Asthma
and Immunology (ACAAI) have jointly accepted responsibil-
ity for establishing ‘‘The Diagnosis and Management of
Anaphylaxis Practice Parameter: 2010 Update.’’ This is a
complete and comprehensive document at the current time.
The medical environment is a changing environment, and
not all recommendations will be appropriate for all patients.
Because this document incorporated the efforts of many par-
ticipants, no single individual, including those who served on
the Joint Task Force, is authorized to provide an official
AAAAI or ACAAI interpretation of these practice parame-
ters. Any request for information about or an interpretation
of these practice parameters by the AAAAI or ACAAI should
be directed to the Executive Offices of the AAAAI, the
ACAAI, or the Joint Council of Allergy, Asthma and Immu-
nology. These parameters are not designed for use by pharma-
ceutical companies in drug promotion.
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PREFACE
This is the third iteration of this parameter entitled ‘‘Thelaxis Parameter was published in 1998, and the second in 2005.
Only the Preface, Significant New Developments, and the Exec-
utive Summary are in the printed version of this update. The entire
document is available online and the reader is referred to that
portion of the document for more detailed discussion of the
comments made in the printed version.
The objective of this parameter is to improve the care of
patients by providing the practicing physician with an evidence-
based approach to the diagnosis and management of anaphylactic
reactions.
The basic format of the document has remained unchanged.
There are two algorithms: one on the evaluation of the patient who
presents to the physician’s office with a previous episode of
anaphylaxis or a condition simulating an anaphylactic event, and
the other on the suggested management of an episode occurring in
the office. Only minor revisions have been made in these
algorithms.
The annotations explaining the steps of the algorithms have
been modestly altered in order to include more recent diagnostic
tests and potential therapies. This edition retains all of the
sections in the previous version including Anaphylaxis to Foods,
Latex-Induced Anaphylaxis, Anaphylaxis during the Periopera-
tive Period, Seminal Fluid Anaphylaxis, Exercise-Induced
Anaphylaxis, Idiopathic Anaphylaxis, Anaphylaxis to Immuno-
therapy Vaccines, Anaphylaxis to Drugs, and the Prevention of
Anaphylaxis. In addition, a new section on Hymenoptera
Sting-Induced Anaphylaxis has been added. The section on
Anaphylaxis to Drugs has also been expanded with a new
section devoted to anaphylactic reactions to omalizumab and
other biologic agents.
As always, the Joint Task Force on Practice Parameters and the
contributing authors wish to thank the ACAAI, AAAAI, and
JCAAI, for their continued support of parameter development.
The Task Force would also like to thank the contributors to this
parameter who have been so generous of their time and effort.
SIGNIFICANT NEW DEVELOPMENTS
A meeting of experts in the field of allergy and immunology
held at the NIH in 2006 developed a definition of anaphylaxis as
Newer markers for anaphylaxis have been evaluated in hopes
that they may enhance the diagnostic accuracy obtained from
measuring tryptase, histamine, and their metabolites alone. In this
1n. Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the
definition and management of anaphylaxis: Summary report- second National Insti-
tute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis network sym-
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(minutes to hours) with involvement of the skin, mucosal tissue or
both and at least one of the following: a) respiratory compromise;
b) or reduced blood pressure or symptoms of end-organ dysfunc-
tion; 2) two or more of the following that occur rapidly after
exposure to a likely allergen for that patient – involvement of
the skin/mucosal tissue, respiratory compromise, reduced blood
pressure or associated symptoms and/or persistent gastrointesti-
nal symptoms; or 3) reduced blood pressure- after exposure to a
known allergen. (1n)
The World Allergy Organization has suggested that the term
‘‘anaphylactoid reaction’’ be eliminated, and that all episodes
clinically similar to IgE-mediated reactions be called anaphy-
laxis. They recommended that anaphylaxis be divided into
immunologic and non-immunologic reactions, the latter being
synonymous with the older term, ‘‘anaphylactoid,’’ and that
immunologic reactions be divided into those mediated by IgE-
mast cell/basophil mediator release and those occurring through
other immunologic mechanisms (e.g., certain transfusion reac-
tions). (2n) In this document, anaphylaxis will continue to mean
an IgE-mediated reaction and non-IgE mediated reactions pro-
ducing the same clinical response will be referred to as
anaphylactoid.
A group of international experts was convened to determine the
prevalence of anaphylaxis. The best data come from the number
of prescriptions for automatic epinephrine injectors. Using these
data, they came to the conclusion that the prevalence may be as
high as 2%.(3n) It is now clear, from a number of recent studies,
that the prevalence is rising, perhaps most markedly in the
younger age group.(4n) Data also suggest- that there has been an
increase in fatalities(4n-6n) and an increase in hospitalizations
from anaphylaxis.(7n-10n)
There are data providing greater insight into the frequency of
biphasic reactions. - More than one injection may be required to
treat a biphasic or protracted reaction.(11n) Biphasic reactions are
thought to increase the risk of fatal anaphylaxis.(12n-13n)
Anaphylactic reactions are not the sole result of immediate
hypersensitivity mast cell/basophil derived mediators such as
histamine, leukotrienes, and prostaglandins. Other mediator
cascades are recruited (e.g., clotting and complement) including
non-mast cell derived mediators which are responsible for many
of the symptoms that occur in anaphylactic reactions.(14n)
Consistent with these findings, there have been reports of patients
not responding to ‘‘classical therapy’’ with epinephrine, but
improving after the administration of agents such as tranexamic
acid (if anaphylaxis is associated with intravascular coagulation)
(15n) and methylene blue (if anaphylaxis is associated with
hypotension).(16n)
Severe and fatal anaphylactic events can be related not only to
the amount of mediators released, but also to the rapidity of their
degradation. This concept has only thus far been confirmed for
platelet activating factor. Patients with lower levels of platelet
activating factor hydrolase (the enzyme that catabolizes platelet
activating factor) are more susceptible to severe and even fatal
reactions than patients with higher levels of this hydrolase.(17n)
A correlation with decreased serum ACE levels has also been
proposed. (18n)regard the measurement of carboxypeptidase has shown great
promise.(19n)
Patients who become hypotensive should remain recumbent
until the cardiovascular system has been stabilized and they are
completely asymptomatic. Deaths documented with regard to
assuming the upright sitting position prematurely have occurred.
(20n)
The standard needle length found on automatic epinephrine
injectors may be insufficient to enable penetration into the vastus
lateralis muscle (lateral thigh) in individuals having a large
amount of subcutaneous fat overlying this muscle.(21n, 22n)
Insufficient use of epinephrine in children and adults has been
documented in regard to ER treatment, as well as inadequate
prescriptions for auto-injectable epinephrine, and referral to
allergists-immunologists.(23n-25n)
It has recently been re-emphasized that an anaphylactic
reaction to an insect sting may indicate an underlying mast cell
disorder. In a recent article, 34 of 379 patients who developed
anaphylaxis to an insect sting had indolent systemic mast cell
disease or monoclonal mast cell activation syndrome on bone
marrow biopsy, underlining previous recommendations that an-
aphylaxis be considered as a possible presentation for mast cell
disease.(26n)
Anaphylaxis can present as an acute cardiac event (27n,
28n) and without dermatologic manifestations.(29n) In a retro-
spective analysis of anaphylaxis over a ten year period, 15%
presented with chest pain and 7% presented with an arrhyth-
mia.(5n) It has also been shown that there are abundant mast
cells in the human heart and that the number and density of
these cells is increased in patients with ischemic heart disease
and dilated cardiomyopathies.(30n)
REFERENCESposium. J Allergy Clin Immunol 2006;117:391-7. (IV)
2n. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global
use: Report of nomenclature review committee of the World Allergy Organization,
2003. J Allergy Clin Immunol 2004;113:832-6. (IV)
3n. Lieberman PL, Camargo C, Simons FER, et al. Epidemiology of Anaphylaxis:
Findings of the ACAAI Epidemiology of Anaphylaxis Working Group. Ann
Allergy, Asthma and Immunol 2006;97:596-602. (IV)
4n. Shen Y, Li L, Grant J, et al. Anaphylactic deaths in Maryland (US) and Shanghai: a
review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009;186:1-5.
(IIb)
5n. Decker WW, Campbell RL, Manivannan V, et al. The etiology and incidence of an-
aphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Pro-
ject. J Allergy Clin Immunol 2008;122(6):1161-5. (III)
6n. Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Aus-
tralia. J Allergy Clin Immunol 2009;123:434-42. (III)
7n. Poulas LM, Waters AM, Correll DK, et al. Trends in hospitalization for anaphy-
laxis, angioedema, and uriticaria in Australia, 1993-1994 to 2004-2005. J Allergy
Clin Immunol 2007;120:878-84. (III)
8n. Gupta R, Sheikh A, Strachan DP, Anderson HR. Time trends in allergic disorders in
the UK. Thorax 2007;62:91-6. (III)
9n. Lin RY, Anderson AS, Shah SN, Nurruzzaman F. Increasing anaphylaxis hospital-
ization in the first two decades of life: New York State, 1990-2006. Ann Allergy
Asthma Immunol 2008;101:387-93. (III)
10n. Simon MR, Mulla ZD. Hospitalizations for anaphylaxis in Florida: Analysis of
month of discharge. Int Arch Allergy Immunol 2008;146:89-90. (III)
11n. Kornblatt P, Lundie MJ, Dankner RE, Day JH. A retrospective study of epineph-
rine administration for anaphylaxis. How many doses are needed? Allergy Asthma
Proc 1999;20:383-6. (III)
(3) Were there gastrointestinal symptoms, i.e., nausea, vomit-
ing, diarrhea?
(4) Were syncope or presyncopal symptoms present?
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ANNOTATIONS – FIG E1
Annotation 1: Is the history consistent with abe made only after other causes of anaphylaxis and otherprevious episode of anaphylaxis?
All individuals who have had a known or suspected anaphy-
lactic episode require a careful and complete review of their
clinical history. This history may elicit manifestations such as
urticaria, angioedema, flushing, pruritus, upper airway obstruc-
tion, gastrointestinal symptoms, syncope, hypotension, lower
airway obstruction, and/or other less common manifestations.
Of primary importance is the nature of the symptoms charac-
terizing the event. Essential questions to be asked are:
(1) Were there cutaneous manifestations (specifically pruritus,
flushing, urticaria, or angioedema)?
(2) Was there any sign of airway obstruction involving either
the upper airway or the lower airway?The absence of cutaneous symptoms puts the diagnosis in
question since the majority of anaphylactic episodes include
cutaneous symptoms (Table E1), although their absence does not
rule out anaphylaxis.The history should concentrate on agents
encountered before the reaction. Whenever appropriate, the
information should be obtained from not only the patient but
also from family members or other witnesses of the event. The
complete sequence of events must be reviewed, with special
attention paid to cardiorespiratory symptoms. Medical records,
including medication records, can often be useful in evaluating
the history, physical findings, and treatment of the clinical event.
In addition, the results of any previous laboratory studies (e.g.,
serum tryptase) may be helpful in making the diagnosis of
anaphylaxis or distinguishing it from other entities.
Annotation 1A: Consider consultation with
allergist/immunologist
Evaluation and diagnosis, as well as long-term management,
can be complex. The allergist/immunologist has the training and
expertise to obtain a detailed allergy history; coordinate labora-
tory and allergy testing; evaluate the benefits and risks of
therapeutic options; and counsel the patient on avoidance mea-
sures. For these reasons, patients with a history of anaphylaxis
should be considered for referral to an allergy/immunology
specialist.
Annotation 2: Pursue other diagnoses or make
appropriate referral
Other conditions that should be considered in the differential
diagnosis include: (1) vasodepressor (vasovagal/neuro-cardio-
genic) syncope; (2) syndromes that can be associated with
flushing (e.g., metastatic carcinoid); (3) postprandial syn-
dromes (e.g., scombroid poisoning); (4) systemic mastocytosis;
(5) psychiatric disorders that can mimic anaphylaxis such as
panic attacks or vocal cord dysfunction syndrome; (6) angio-
edema (e.g., hereditary angioedema); (7) other causes of shock
(e.g., cardiogenic); and (8) other cardiovascular or respiratory
events.
Annotation 3: Is cause readily identified by history?
The history is the most important tool to establish the cause of
anaphylaxis and takes precedence over diagnostic tests.
A detailed history of all food consumed and drugs taken over
the four to six hours prior to the episode should be obtained. In
addition, the labels for all packaged foods ingested by the patient
in this period of time should be reviewed since a substance added
to the food could be responsible. A history of any preceding bite
or sting should be obtained. The patient’s activities (e.g., exercise,
sexual activity) preceding the event should be reviewed. Patient
diaries may be a useful adjunct in confirming or identifying the
cause of anaphylaxis.
Annotation 4: Consider idiopathic anaphylaxis
Idiopathic anaphylaxis is a diagnosis of exclusion that shoulddifferential diagnoses have been considered.
Annotation 5: Are further diagnostic tests indicated:
allergy skin tests or in vitro tests, challenge tests?
Annotation 8: Reconsider clinical diagnosis;
reconsider idiopathic anaphylaxis; consider other
J ALLERGY CLIN IMMUNOL
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challenge tests may be appropriate to help define the cause of
the anaphylaxis. However, the history may be so conclusive that
none of these tests are necessary.
Annotation 6: Diagnosis established on basis of
history; risk of testing; limitation of tests; patient
refuses test; other management options available;
management
Theremay be circumstances where skin tests or in vitro specific
IgE, and/or challenge tests may not be warranted. In general, this
may apply when the clinician decides to proceed with manage-
ment because the history is conclusive. The history of anaphylaxis
to a specific agent may be so strong that testing is unnecessary and
inappropriate from the benefit: risk standpoint. If avoidance can
be easily and safely accomplished, testing may not be necessary.
Testing or challenge with reagents to a suspected allergen may
not be available, or the predictive value of the test may be in
question. Challenge tests (and, to a lesser extent, skin tests) may
be hazardous, and not acceptable from a benefit: risk standpoint, if
other management options are available. Occassionally patients
may refuse to have the test.
Annotation 7: Testing identifies specific cause of
anaphylaxis
Skin tests or in vitro tests can determine the presence of specific
IgE antibodies to foods, medications (e.g., penicillin and insulin),
and stinging insects as a cause of anaphylaxis.. For themajority of
medications, standardized in vivo and/or in vitro testing is not
available.
In general, skin testing is more sensitive than in vitro testing
and is the diagnostic procedure of choice for evaluation of most
potential causes of anaphylaxis (e.g., penicillin and insect stings).
It is essential, however, that the correct technique for skin testing
be used. When possible, standardized extracts for skin testing
should be used, although occasionally fresh food extracts will
be superior to available standardized extracts. If the skin testing
extract has not been standardized (e.g., latex, protamine, or anti-
biotics other than penicillin), the clinical relevance of the results
may be uncertain. If skin testing is performed, it should be done
under the supervision of a physician who is experienced in the
procedure in a setting with appropriate rescue equipment and
medication.
The accuracy of in vitro testing depends on the reliability of the
in vitro method, the ability to interpret the results, and the avail-
ability of reliable testing material. The clinical significance of
skin testing or in vitro test depends on the ability to correlate
the results of such testing with the patient’s history.
If tests for specific IgE antibodies (i.e., skin tests, in vitro tests,
or both) do not provide conclusive evidence of the cause of ana-
phylaxis, challenge with the suspected agent can be considered.
Challenge procedures may also be appropriate in patients who
develop non-IgE-mediated reactions (e.g., reactions to aspirin
(ASA) or other nonsteroidal anti-inflammatory drugs (NSAIDs).
Challenge with suspected agents must be done carefully by indi-
viduals knowledgeable in the challenge procedure and with
expertise in managing reactions to the challenge agent if they
should occur.triggers; consider further testing; management
At this stage in the patient’s evaluation, it is particularly
important to consider other possible causes of anaphylaxis or a
different diagnosis. The history and test results should be
reviewed. Further testing for specific IgE antibodies should be
considered. Laboratory studies that may be helpful include:
serum tryptase, as well as urinary 5-hydroxyindoleacetic acid,
methylhistamine, and catecholamines. Idiopathic anaphylaxis is a
diagnosis of exclusion (see section on idiopathic anaphylaxis).
Management of anaphylaxis should follow annotation 10 (see
below).
Annotation 9: Diagnosis made of specific cause of
anaphylaxis
The diagnosis of a specific cause of anaphylaxis may be
supported by the results of skin tests, in vitro IgE tests, and/or
challenge tests (particularly double-blind, placebo-controlled
challenge tests).
Annotation 10: Management of anaphylaxis
When anaphylaxis has occurred because of exposure to a
specific agent (e.g., food, medication, or insect sting), patients
should be educated about agents or exposures that would place
them at risk for future reactions and be counseled on avoidance
measures that may be used to reduce risk for such exposures.
Patients who have had anaphylactic reactions to food should be
instructed on how to read food ingredient labels to identify foods
that they should avoid. Patients with anaphylaxis to medications
should be informed about all cross-reacting medications that
should be avoided. Should there be a future essential indication
for use of incriminated medications, it may be helpful to educate
patients about applicable management options (e.g., medication
pretreatment and use of low osmolarity agents in patients with a
history of reactions to radiographic contrast media or desensitiz-
ation for drugs such as antibiotics). Patients who have had an
anaphylactic reaction to an insect sting should be advised about
avoidance measures to reduce the risk of an insect sting and
usually are candidates for insect venom immunotherapy. Patients
who have had anaphylaxis should carry self-injectable epineph-
rine if there is continued risk for anaphylaxis. Patients should also
carry identification indicating that they have experienced ana-
phylaxis and indicating the responsible agent.
ANNOTATIONS – FIG E2
Annotation 1. Anaphylaxis Preparedness
Management recommendations are subject to physician dis-
cretion as well as practice resources and the proximity to
emergency assistance. Variations in sequence and performance
rely on physician judgment. A determination of when a patient
should be transferred to an emergency facility depends on the
skill, experience and clinical decision-making of the individual
physician. Prompt recognition and appropriate, aggressive treat-
ment are essential for the successful management of anaphylaxis.
Stocking and maintaining supplies for the treatment of ana-
phylaxis with regular written documentation of supplies and
expiration dates and ready availability of injectable epinephrine,
intravenous fluids and needles, oxygen and mask/cannula, airway
adjuncts, and stethoscope and sphygmomanometer are bare
essentials. (An example of a supply checklist is included in
Section VI, ‘‘Management of Anaphylaxis’’)
Regular anaphylaxis practice drills, the makeup of which is left
decreased when accompanied by symptomatic bradycardia but
it may be normal, and the skin is typically cool and pale. While
tachycardia is the rule, bradycardia may occur during anaphy-
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strongly recommended. It is essential to identify a person who
will be responsible for calling emergency medical services and
the person who will document each treatment and the time that
each is rendered. Emergency medications should be up-to-date
and complete. Everyone who will be directly involved in patient
care should be able easily to locate necessary supplies, rapidly
assemble fluids for intravenous administration, and be prepared to
begin treatment so that no time is lost in implementing emergency
measures.
Annotation 2. Patient Presents with Possible/
Probable Acute Anaphylaxis
Anaphylaxis is an acute life-threatening reaction, usually butnot always mediated by an immunologic mechanism, that results
from the sudden systemic release of mediators from mast cells
and basophils. Anaphylaxis has varied clinical presentations but
respiratory compromise and cardiovascular collapse are of
greatest concern, since they are the most frequent causes of
fatalities. Urticaria and angioedema are the most common
manifestations of anaphylaxis but may be delayed or absent
especially in rapidly progressive anaphylaxis. The more rapid
anaphylaxis occurs after exposure to an offending stimulus, the
more likely the reaction is to be severe and potentially life-
threatening.
Anaphylaxis often produces signs and symptoms within min-
utes of exposure to an offending stimulus but some reactions may
develop later (e.g., greater than 30min after exposure). Late phase
or ‘‘biphasic’’ reactions, which occur 1 to 72 hr (most within 10
hr) after the initial attack, have also been reported. Protracted,
severe anaphylaxis may last up to 32 hr despite aggressive
treatment.
Increased vascular permeability, a characteristic feature of
anaphylaxis, allows transfer of as much as 35% of the intravas-
cular fluid into the extravascular space within 10 min. As a result,
hemodynamic collapse may occur rapidly with little or no
cutaneous or respiratory manifestations.
Annotation 3. Initial Assessment of Possible/
Probable Anaphylaxis
Initial assessment should determine if history and physical
findings are compatible with anaphylaxis. The setting of the
episode and the past history may suggest or reveal the source of
the reaction. Evaluation should include: level of consciousness
(impairment may reflect hypoxia), upper and lower airways
(dysphonia, stridor, cough, wheezing, shortness of breath), car-
diovascular system (hypotension with or without syncope; and/or
cardiac arrhythmias), the skin (diffuse or localized erythema,
pruritus, urticaria and/or angioedema), and the gastrointestinal
system (nausea, vomiting, diarrhea). In addition, some patients
may have symptoms of lightheadedness, headache, uterine
cramps, feeling of impending doom, and unconsciousness.
The vasodepressor (vaso-vagal) reaction probably is the con-
dition most commonly confused with anaphylactic reactions. In
vasodepressor reactions, however, urticaria is absent, the heart
rate is typically bradycardic, bronchospasm or other breathing
difficulty is generally absent, the blood pressure is oftenlaxis, so bradycardia may not be as useful to separate anaphylaxis
from a vasodepressor reaction as has previously been thought.
Relative bradycardia (initial tachycardia followed by a reduction
in heart rate despite worsening hypotension) has been reported
previously in the setting of experimentally induced insect sting
anaphylaxis and in other states of hypovolemia (e.g., trauma).
Tachycardia may also be absent in patients with conduction
defects, increased vagal tone due to a cardioinhibitory (Bezold-
Jarisch) reflex, or in those who take sympatholytic medications.
Annotation 4. Consider Other Diagnosis
Other diagnoses that might present with signs and/or symptoms
characteristic of anaphylaxis should be excluded. Among condi-
tions to consider are vasodepressor (vasovagal) reactions, vocal
cord dysfunction, acute anxiety (e.g., panic attack or hyperven-
tilation syndrome), myocardial dysfunction, pulmonary embo-
lism, foreign body aspiration, acute poisoning, hypoglycemia,
and seizure disorder. Specific signs and symptoms of anaphylaxis
may be in other disorders such as urticaria/angioedema, and
asthma.
Annotation 5. Immediate Intervention
Anaphylaxis occurs as part of a continuum. Symptoms not
immediately life-threatening may progress rapidly unless treated
promptly. Treatment recommendations are subject to physician
discretion and variations in sequence and performance rely on
physician judgment. Additionally, a determination of when a
patient should be transferred to an emergency or intensive care
facility depends on available resources and the skill, experience
and clinical decision-making of the individual physician.
a) Assess airway, breathing, circulation, and level of con-
sciousness (altered mentation may suggest the presence of
hypoxia).
b) Administer epinephrine. Aqueous epinephrine 1:1000 dilu-
tion (1 mg/ml), 0.2-0.5 ml (0.01 mg/kg in children, max 0.3
mg dosage) intramuscularly in the lateral aspect of the thigh
or subcutaneously every 5 min, as necessary, to control
symptoms and increase blood pressure. If the clinician
deems it appropriate, the 5-minute interval between injec-
tions can be liberalized to permit more frequent injections.
Intramuscular epinephrine injections into the thigh have
been reported to provide more rapid absorption and higher
plasma epinephrine levels in both children and adults than
intramuscular or subcutaneous injections administered in
the arm. However, similar studies comparing intramuscular
injections to subcutaneous injections in the thigh have not
been done. These studies were not performed in patients ex-
periencing anaphylaxis. The generalizability of these find-
ings to the clinical setting of anaphylaxis has not been
established. There are no studies that support the use of ep-
inephrine in the treatment of anaphylaxis when delivered by
a non-parenteral route. However, alternative routes of ad-
ministration have been anecdotally successful. These in-
clude, for example, inhaled epinephrine in the presence of
laryngeal edema or sublingual administration if an intrave-
nous route cannot be obtained. Endotracheally administered
dosages have also been proposed for use when intravenous
access is not available in intubated patients experiencing
cardiac arrest.
Annotation 7. Subsequent Measures That May Be
Necessary Depending on Response to Epinephrine
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Necessary Depending on Response to Epinephrine
a) Consider calling 911 and obtaining assistance.
b) Place the patient in a recumbent position and elevate the
lower extremities, as tolerated symptomatically. This slows
progression of hemodynamic compromise, if present, by
preventing orthostatic hypotension and helping to shunt ef-
fective circulation from the periphery to the head, the heart
and kidneys.
c) Establish and maintain an airway. Ventilatory assistance via
a one-way valve facemask with oxygen inlet port (e.g.,
Pocket-MaskR or similar device) may be necessary. Bag
valve masks of less than 700 ml are discouraged in adults
in the absence of an endotracheal tube since ventilated vol-
ume will not overcome 150-200 ml of anatomic dead space
to provide effective tidal volume. (Bag valve masks may be
used in children provided the reservoir volume of the device
is sufficient.) Endotracheal intubation or cricothyroidotomy
may be considered where appropriate, provided clinicians
are adequately trained and proficient in this procedure.
d) Administer oxygen. Oxygen should be considered for pa-
tients with anaphylaxis who have prolonged reactions,
have pre-existing hypoxemia or myocardial dysfunction, re-
ceive inhaled b-agonists as part of the treatment for anaphy-
laxis, or who require multiple doses of epinephrine.
Continuous pulse oximetry and/or arterial blood gas deter-
mination (where available) should guide oxygen therapy, es-
pecially in high risk patients, .e.g. patients with COPD.
e) Rapid intravenous fluid replacement should be started when
the patient has failed to respond to the treatment as outline
above. Administration and dosage of intravenous fluids are
discussed under the section on ‘‘Anaphylaxis Treatment’’.
f) Consider diphenhydramine, 1-2 mg/kg or 25-50 mg/dose
(parenterally). H1 antihistamines are considered second-
line to epinephrine and should not be administered in lieu
of epinephrine in the treatment of anaphylaxis.
g) Consider ranitidine, 50 mg in adults and 12.5-50 mg (1 mg/
kg) in children, which may be diluted in 5% dextrose to a
total volume of 20 ml and injected IV over 5 min. Cimeti-
dine (4 mg/kg) may be administered IV to adults, but no pe-
diatric dosage for the treatment of anaphylaxis has been
established. In the management of anaphylaxis, a combina-
tion of diphenhydramine and ranitidine is superior to
diphenhydramine alone. However, these agents have a
much slower onset of action than epinephrine and should
never be used alone in the treatment of anaphylaxis. Both
alone and in combination these agents are second-line to
epinephrine.
h) Consider inhaled ß-agonist (e.g., albuterol MDI 2-6 puffs or
nebulized, 2.5-5 mg in 3 ml saline and repeat as necessary)
for bronchospasm resistant to adequate doses of
epinephrine.
i) Glucocorticosteroids should never be used in place of or
prior to epinephrine and are not helpful acutely. However,
they have the potential to prevent recurrent or protracted
anaphylaxis.When anaphylaxis is not responding to the above measures,
including repeated doses of IM or SQ epinephrine, the use of IV
epinephrine, vasopressors and glucagon may need to be consid-
ered. (See section on Anaphylaxis Treatment.)
Annotation 8. Interventions for Cardiopulmonary
Arrest Occurring during Anaphylaxis
a) Cardiopulmonary resuscitation and advanced cardiac life
support measures.
b) High-dose epinephrine IV (i.e., rapid progression to high
dose). A common sequence is 1 to 3 mg (1:10,000 dilution)
IV slowly administered over 3 min, 3 to 5 mg IVover 3 min,
and then 4-10mg/min infusion. For children, the recommen-
ded initial resuscitation dosage is 0.01mg/kg (0.1 ml/kg of a
1:10,000 solution up to 10mg/min rate of infusion), repeated
every 3 to 5 min for ongoing arrest. Higher subsequent dos-
ages (0.1-0.2mg/kg; 0.1ml/kg of a 1:1,000 solution) may be
considered for unresponsive asystole or pulseless electrical
activity (PEA).
c) Rapid volume expansion.
d) Atropine if asystole or pulseless electrical activity (PEA) is
present.
e) Prolonged resuscitation is encouraged, if necessary, since a
successful outcome is more likely in anaphylaxis.
f) Transport to emergency department or intensive care, as set-
ting dictates.
Annotation 9. Observation and Subsequent
Follow-Up
Biphasic anaphylaxis occurs in 1% to 23% of episodes of
anaphylaxis, and symptoms may recur hours (most within 10
hours) after apparent resolution of the initial phase. However,
observation periods must be individualized since there are no
reliable predictors of biphasic or protracted anaphylaxis based
on initial clinical presentation. Similarly, follow-up must be
individualized and based on distance from patient’s home to
closest emergency facility, severity of the reaction, patient’s
response to treatment, and other factors. Following resolution of
the acute episode, patients should be provided with autoinject-
able epinephrine and receive proper instruction for self-
administration in case of a subsequent episode. In circumstances
where an allergist-immunologist is not already involved, it is
strongly recommended that individuals who have experienced
acute anaphylaxis should be referred to an allergist-
immunologist for consultation regarding diagnosis, prevention,
and treatment.
Annotation 10. Consultation with Allergist-
Immunologist
After acute anaphylaxis is resolved, patients should be assessed
for future risk of anaphylaxis. The allergist-immunologist can
obtain a detailed history, coordinate allergy diagnostic testing,
evaluate the risks and benefits of therapeutic options, train the
patient in self-administration of epinephrine, and provide coun-
seling on avoidance measures, which is the most effective
treatment for most causes of anaphylaxis.
EVALUATION AND MANAGEMENT OF PATIENTS
WITH A HISTORY OF ANAPHYLAXIS
Differential Diagnosis
The differential diagnosis must be considered whenever the
history is taken, even in patients with a previous history of
tryptase and plasma and urinary histamine levels can sometimes be
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1. The history is the most important tool to determine
whether a patient has had anaphylaxis and the cause of
the episode. C
2. A thorough differential diagnosis should be considered,
and other conditions should be ruled out. C
3. Laboratory tests can be helpful to confirm a diagnosis of
anaphylaxis or rule out other causes. Proper timing of
such tests (e.g., serum tryptase) is essential. B
4. In the management of a patient with a previous episode
of anaphylaxis, education is necessary. Emphasis on
early treatment, specifically the self-administration of
epinephrine, is essential. C
5. The patient can be instructed to wear and/or carry iden-
tification denoting his or her condition (e.g., Medic Alert
jewelry), and can also be instructed to have telephone
numbers for paramedic rescue squads and ambulance
services on hand. A written action plan can be helpful
in this regard. C
Performing the History
To interpret the history adequately it is essential to know the
manifestations of anaphylaxis. These can best be ascertained by a
review of published series on the topic.1-12 A summary of the
signs and symptoms as reported in these series, totaling 1,865 pa-
tients, is seen in Table E1. These series include patients of all
ages suffering from exercise-induced anaphylaxis, idiopathic an-
aphylaxis, and from various other causes. The most frequent
manifestations of anaphylaxis are cutaneous, occurring in over
90% of reported series. The absence of cutaneous symptoms
speaks against a diagnosis of anaphylaxis, but does not rule it
out. Severe episodes characterized by rapid cardiovascular col-
lapse and shock can occur without cutaneous manifestations.13,15
To better assess the signs and symptoms of the reaction, friends
and/or family members present during the event may sometimes
need to be interviewed. Anaphylaxis can present with unusual
manifestations, e.g., syncope without any other sign or symp-
tom.13,15 Additionally, based on studies limited to children, the
incidence of cutaneous manifestations in children may be
lower.16-17
The history and the record should include the time of the
occurrence of the attack, the setting in which it occurred, any
treatment required during the attack, and the duration of the
episode. A detailed history of all potential causes should be
obtained. This includes a list of ingestants consumed and/or
medications taken within six hours of the event, any sting or bite
occurring prior to the event, if the event occurred during exercise,
location of the event (e.g., work versus home), and whether or not
the event was related to exposure to heat, cold, or occurred during
sexual activity. The patient’s atopic status should be noted since
food-induced, seminal fluid and idiopathic anaphylaxis are more
common in atopic than non-atopic individuals. In women, the
history should include any relationship between the attack and
their menstrual cycle. A return of symptoms following a remis-
sion should be noted since this may indicate a late phase
reaction,18 whichmight require a prolonged period of observation
if subsequent events occur.anaphylaxis. A comprehensive differential diagnoses is seen in
Table E2. Vocal cord dysfunction and panic attacks should be
considered in the differential diagnosis.
Special attention in the differential diagnosis should be given to
vasodepressor (vasovagal) reactions. Characteristic features of
this reaction include hypotension, pallor, weakness, nausea,
vomiting, and diaphoresis. Such reactions can often be distin-
guished from anaphylaxis by a lack of characteristic cutaneous
manifestations (urticaria, angioedema, flush, pruritus) and the
presence of bradycardia during the vasodepressor reaction instead
of tachycardia usually seen with anaphylaxis. However, it should
be noted that bradycardia can occur during anaphylaxis as well19.
This is probably due to the Bezold-Jarisch reflex, a cardioinhibi-
tory reflex that has its origin in sensory receptors in the inferopos-
terior wall of the left ventricle. Unmyelinated vagal C fibers
transmit the reflex. Bradycardia occurs immediately with a vaso-
depressor event, but in anaphylaxis, tachycardia often precedes
the onset of bradycardia.19
Flushing episodes can mimic anaphylactic events. Several
drugs and ingestants including niacin, nicotine, catecholamines,
ACE inhibitors, and alcohol can induce flushing20. Other
conditions that cause flushing must be considered, including ro-
sascea, gastrointestinal and thyroid tumors, carcinoid syndrome,
pheochromocytoma, hyperglycemia, postmenopausal flush,
alcohol-induced flushing, and the ‘‘red man syndrome’’ due to
the administration of vancomycin. Laboratory studies (Table
E3) can be helpful in establishing if the patient is experiencing
anaphylaxis.
There are a group of postprandial syndromes that can mimic
anaphylaxis, such as monosodium glutamate-induced reaction,
and reactions to scombroid fish. The latter is increasing in
frequency21 and since it is due to histamine produced by
histidine-decarboxylating bacteria that cleave histamine from his-
tidine in spoiled fish, the symptoms can be identical to those that
occur in anaphylaxis. However, the cutaneous manifestation may
be more of a flush (sunburn-like) than urticaria. Symptoms may
affect more than one individual if they also ingested the fish caus-
ing the reaction and serum tryptase levels are normal.
Laboratory Studies
Laboratory studies to be considered are seen in Table E3. Serumhelpful in establishing the diagnosis of anaphylaxis.22-31 Plasma
histamine levels begin to rise within 5 to 10 minutes of the onset
of symptoms of anaphylaxis and remain elevated for 30 to 60 min-
utes.25,27 Therefore, they are not of help if the patient is seen as
long as an hour or more after the onset of the event.28 However uri-
nary methyl-histamine levels are elevated for a longer duration of
time.29 Serum tryptase levels peak one to one and one-half hours
after the onset of anaphylaxis and can persist for as long as five
hours after the onset of symptoms.25 The best time to measure se-
rum tryptase is between one to two hours but no longer than six
hours after the onset of symptoms.25 The best time to measure
plasma histamine is between 10 minutes and one hour after the on-
set of symptoms.25 It should be noted that there can be a discon-
nection between histamine and tryptase levels with some
patients exhibiting elevation of only one of these mediators.24,25
It was originally thought that tryptase was present in an alpha
and ß form, and that alpha tryptase comprised the majority of
constitutively secreted tryptase. Subjects with null alleles for
8. Prompt recognition of signs and symptoms of anaphy-
laxis is crucial. If there is any doubt, it is generally bet-
ter to administer epinephrine. C
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known that constitutively secreted tryptase is, for the most part, b
-pro tryptase (immature b tryptase) with alpha tryptase contrib-
uting only a small, negligible amount. 26 Upon mast cell degran-
ulation there is a marked increase in tryptase which is composed
of mature b tryptase. Thus, constitutively secreted tryptase is a
mixture of alpha (in modest amounts) and b -pro tryptase (imma-
ture tryptase) (the majority amount). Marked increases in total
tryptase are seen during an anaphylactic event. This is due to
the rise in mature b tryptase released only during degranulation.27
It has been proposed that elevations of postmortem serum
tryptase be used to establish anaphylaxis as a cause of death.28
However, it should be clearly noted that postmortem elevation of
serum tryptase concentrations is not a specific finding and therefore
cannot be considered diagnostic of an anaphylactic death. There
are reports of non-anaphylactic deaths with elevated postmortem
serum tryptase levels.29-31 Thus, the presence of an elevated post-
mortem tryptase level cannot be considered pathognomonic for a
death due to anaphylaxis. Nor can an absence of an elevated serum
tryptase postmortem be considered sufficient to rule out anaphy-
laxis as the cause of death.29 In patientswith a possible anaphylaxic
reaction to food, leftover or vomited foodmay be useful as a source
of antigen for the creation of an in-vitro test reagent.28
Total tryptase levels can be elevated in conditions other than
mastocytosis and anaphylaxis, such as acute myelocytic leukemia,
hypereosinophilic syndrome associated with the F1P1 L1-
PDGFRA mutation, myelodysplastic syndromes, and end-stage
renal diseasewith endogenous stemcell factor elevation.22Because
of this, other markers for mast cell degranulation are being evalu-
ated. Particularly promising is mast cell carboxypeptidase A3.
Also being studied are platelet activating factor and chymase.32 It
is of note that platelet activating factor and its hydrolase are both
measureable and that the severity of anaphylaxis is directly corre-
lated with serum levels of platelet activating factor and inversely
correlated with serum levels of platelet activating factor hydrolase.
If a patient has had a previous episode of anaphylaxis, the
patient needs to be educated about the need for early treatment of
any subsequent episodes, in particular, the self-administration of
epinephrine. Patients who have experienced an episode of ana-
phylaxis can also carry identification denoting their possible
susceptibility to future episodes. This can consist of a card and/or
identification jewelry (e.g., Medic Alert).
Medical facilities should have an established protocol to
manage anaphylaxis and the appropriate equipment to treat an
anaphylactic reaction. In addition, telephone numbers for para-
medical rescue squads and ambulance services might be helpful
to have on hand.
OFFICE MANAGEMENT OF ANAPHYLAXIS
Summary Statements6. Anaphylaxis is an acute, life-threatening systemic reac-
tion with varied mechanisms, clinical presentations,
and severity that results from the sudden systemic
release of mediators from mast cells and basophils. B
7. The more rapidly anaphylaxis develops, the more likely
the reaction is to be severe and potentially life-
threatening. C9. Epinephrine and oxygen are the most important thera-
peutic agents administered in anaphylaxis. Epinephrine
is the drug of choice, and the appropriate dose should be
administered promptly at the onset of apparent ana-
phylaxis. The consensus of experts is that, in general,
treatment in order of importance is: epinephrine, pa-
tient position, oxygen, intravenous fluids, nebulized
therapy, vasopressors, antihistamines, corticosteroids,
and other agents. C
10. Appropriate volume replacement either with colloid or
crystalloids and rapid transport to the hospital is essen-
tial for patients who are unstable or refractory to initial
therapy for anaphylaxis in the office setting. B
11. Medical offices and facilities in which anaphylaxis is
possible should have a well established plan of action
to deal with anaphylaxis that is regularly practiced
and the appropriate equipment to treat anaphylaxis.
The more rapid the treatment, the better the outcome.
Therefore, personnel in a medical office dealing directly
with the patient’s medical care should be familiar with
the manifestations of anaphylaxis and be able to recog-
nize an event quickly. Access to therapy should be im-
mediately available. B
12. Physicians and office staff should maintain clinical pro-
ficiency in anaphylaxis management. D
13. In addition, telephone numbers for paramedical rescue
squads and ambulance services might be helpful to have
on hand. C
The management of anaphylaxis is summarized in algorithmic
form in Fig E2. Appropriate management requires adequate
supplies, and a list of these supplies is noted in Fig E3. The
following equipment and supplies should be available:33-35 (1)
Stethoscope and sphygmomanometer; (2) injectable aqueous ep-
inephrine 1:1000; (3) oxygen and equipment for administering it;
(4) intravenous fluids and equipment for administering them, and
(5) tourniquets, syringes, hypodermic needles, large-bore needles
(e.g., 14- or 16-gauge); The following equipment and supplies
should be considered depending on the availability of emergency
support services (1) one-way valve facemask with oxygen inlet
port (e.g., Pocket-Mask or similar device); (2) diphenhydra-
mine or similar injectable antihistamine; (3) corticosteroids for
intravenous injection; and possibly (4) a vasopressor (e.g., dopa-
mine or norepinephrine). Some clinicians may strongly consider
having available glucagon, an automatic defibrillator, and/or oral
airway depending on the clinical setting.
EPINEPHRINE
The initial drug of choice is epinephrine.33-37 The following are
salient points regarding administration of epinephrine:
d The concentration is 1:1000 and the adult dose is 0.2 to 0.5
ml (mg). The dose in a child is 0.01 ml (mg)/kg.
d The time to highest blood concentration (Cmax), when
studied in asymptomatic subjects, is shorter when injec-
tion is given intramuscularly in the vastus lateralis mus-
cle (lateral thigh) than when it is administered either
subcutaneously or intramuscularly in the deltoid muscle
of the arm. There are no outcome data comparing these
routes of administration during anaphylaxis. There are
no data indicating that epinephrine is ineffective when
administered either subcutaneous or intramuscular in
intravenous epinephrine is considered under these spe-
cial circumstances, monitoring by available means (e.g.,
every-minute blood pressure and pulse measurements
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d Epinephrine may be administered every 5 to 10 minutes
as necessary. If the clinician deems it appropriate, the 5
minute interval between injections can be liberalized to
promote more frequent administration.
d Epinephrine should be administered as soon as the diag-
nosis of anaphylaxis is suspected.
d Although the diagnosis of anaphylaxis usually depends on
involvement of two organ systems (e.g., skin plus respira-
tory, skin plus cardiovascular), anaphylaxis may present
as an acute cardiac or respiratory event or with hypoten-
sion as the only manifestation of anaphylaxis.
d The case of suspected anaphylaxis even if it involves only
one system, such as the skin, epinephrine administration
may be indicated.
d Intravenous administration may be considered in pa-
tients poorly responsive to intramuscular or subcutane-
ous epinephrine, where there is inadequate time for
emergency transport or prolonged transport is required.
No established dosage or regimen for intravenous epi-
nephrine in anaphylaxis is recognized. However, a pro-
spective study demonstrated the efficacy of a 1:100,000
solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100
ml saline) intravenously by infusion pump at an initial
rate of 30-100 ml/hr (5-15 mg/min), titrated up or down
depending on clinical response or epinephrine side effects
(toxicity). Inferences regarding intravenous dosing may
also be drawn from the emergency cardiac care consen-
sus guidelines for intravenous epinephrine for adults
and children.37,38 An epinephrine infusion may be pre-
pared by adding 1 mg (1 ml) of 1:1000 dilution of epi-
nephrine to 250 ml of D5W to yield a concentration of
4.0 mg/ml. This 1:250,000 solution is infused at a rate of
1mg/min (15 drops/minute using a micro-drop apparatus
[60 drops/minute5 1 ml5 60 ml/hr]), titrated to desired
hemodynamic response, increasing to a maximum of 10.0
mg/min for adults and adolescents. A dosage of 0.01 mg/
kg (0.1 ml/kg of a 1:10,000 solution up to 10mg/min;
maximum dose, 0.3 mg) is recommended for children.
Alternative pediatric dosage by the ‘‘Rule of 6’’ is, as
follows: 0.6 X body weight (in kg) 5 # of mg diluted
to total 100 ml saline; then 1ml/hr delivers 0.1 mg/kg/
min. 39 (See Table E4 for infusion guidelines in children.)
An alternative epinephrine infusion protocol has been
suggested for adults with anaphylaxis.19
d Because of the risk of potentially lethal arrhythmias, epi-
nephrine should be administered intravenously only in
profoundly hypotensive patients or patients in cardio/res-
piratory arrest who have failed to respond to intravenous
volume replacement and several injected doses of epineph-
rine. In situations where hemodynamic monitoring is
available (e.g., emergency department, intensive care facil-
ity), continuous hemodynamic monitoring is recommen-
ded if epinephrine is given intravenously.19 However, use
of intravenous epinephrine should not be precluded in a
scenario where such monitoring is not available, if the cli-
nician deems its administration is essential after several
intramuscular/subcutaneous epinephrine injections. Ifand ECG monitoring, if available) should be considered.
Numerous cases of unusually severe or refractory anaphylaxis
have been reported in patients receiving b -adrenergic
blockers.40-53 Although the pharmacology of provocation or exac-
erbation of bronchospasm with use of b -blockers is well known,
the pharmacodynamics that contribute to greater risk for more
serious anaphylaxis are not as widely recognized.54-56 These sys-
temic effects have also been documented with use of ophthalmic b
-blockers.57 Greater severity of anaphylaxis observed in patients
receiving b -blockers might relate, in part, to a blunted response
to epinephrine administered to treat anaphylaxis.57 Epinephrine
administered to a patient taking a b -blocker can produce unop-
posed a-adrenergic and reflex vagotonic effects, possibly leading
to hypertension and the risk of cerebral hemorrhage.58 In patients
receiving b-blockers, increased propensity not only for broncho-
spasm, but also decreased cardiac contractility with perpetuation
of hypotension and bradycardia might exist.58-60 For these reasons,
b-blocker-related anaphylaxis may be more likely to be refractory
to management. There are no epidemiologic studies that indicate
that anaphylaxis occurs more frequently in patients receiving b-
blockers. In view of b-blocker withdrawal syndromes observed
in selected cases and the clear benefits that may accrue from use
of b-blockers in patients for whom these drugs are indicated, the
decision to withhold or discontinue b -blockers must be consid-
ered carefully from the perspective of risk vs. benefit for each in-
dividual.45-47,61-64 Therefore, patients taking b –blockers may be
more likely to experience severe anaphylactic reactions character-
ized by paradoxical bradycardia, profound hypotension, and
severe bronchospasm. Use of selective b 1-antagonists does not re-
duce the risk of anaphylaxis because both b 1 and b 2- antagonists
may inhibit the b -adrenergic receptor.
If epinephrine is ineffective in treating anaphylaxis in patients
taking b -blockers, both glucagon administration and isotonic
volume expansion (in some circumstances, up to 7 L of crystal-
loid) may be necessary.53,65-69 Glucagon may reverse refractory
bronchospasm and hypotension during anaphylaxis in patients
on b- blockers by activating adenyl cyclase directly and bypass-
ing the b -adrenergic receptor.53,67-69 The recommended dosage
for glucagon is 1 to 5 mg (20-30 mg/kg [max. 1 mg] in children)
administered intravenously over 5 min and followed by an infu-
sion, 5-15 mg/min, titrated to clinical response. Protection of
the airway is important since glucagon may cause emesis and
risk aspiration in severely drowsy or obtunded patients. Place-
ment in the lateral recumbent position may be sufficient airway
protection for many of these patients.
POSITIONING OF PATIENT
Place the patient in a supine position and elevate the lower
extremities, particularly when there is concern for hemodynamic
compromise. This slows the progression of hemodynamic com-
promise by preventing orthostatic hypotension and helping to
shunt effective circulation from the periphery to the head, the
heart and kidneys. Patients who become hypotensive should
remain recumbent until the cardiovascular system has been
stabilized and they are completely asymptomatic.70 Deaths have
occurred if the patient assumes the upright sitting position
prematurely.71
OXYGEN
Oxygen should be administered to patients with anaphylaxis
who have prolonged reactions. Oxygen can be considered in any
High quality randomized controlled trials have not demon-
strated that vasopressin is more effective than epinephrine in the
treatment of cardiac arrest.75-77,80 No controlled studies have
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oxygen treatment.
FLUID RESUSCITATION
The patient whose hypotension persists despite epinephrine
injections should receive intravenous crystalloid solutions or
colloid volume expanders. Of available crystalloid solutions,
saline is generally preferred in distributive shock (e.g., anaphy-
lactic shock) because it stays in the intravascular space longer
than dextrose and contains no lactate which may potentially
exacerbate metabolic acidosis. Large volumes of fluid are often
required, especially in patients taking a b -adrenergic blocking
agent. One to 2 L of normal saline may need to be administered to
adults at a rate of 5-10 ml/kg in the first 5 minutes. Children
should receive up to 30 ml/kg in the first hour. Adults receiving
colloid solution should receive 500 ml rapidly, followed by slow
infusion. Caution for volume overload is advised if the patient has
a history of congestive heart failure.
Clinicians who are adequately trained and proficient at
obtaining intraosseous (IO) access for either adults or children
may consider this approach if attempts at IV access have been
unsuccessful. IO cannulation provides access to a non-collapsible
venous plexus, which is attainable in all age groups and several
studies have documented its safety and efficacy. Fluids adminis-
tered IO for volume replacement should be infused under pressure
using an infusion pump, pressure bag, or manual pressure to
overcome venous resistance. Less than 1% of patients have
complications after an IO infusion.72,73
INHALED b2 ADRENERGIC AGONISTS
For patients who develop bronchospasm, an inhaledb 2 agonist
can be helpful, especiallywhen bronchospasmdoes not respond to
epinephrine. There is anectdotal evidence that inhaled epineph-
rine can be effective in anaphylaxis and that inhaled b 2 agonists
might be helpful, especially for upper airway obstruction.
VASOPRESSORS
Vasopressors, such as dopamine (400mg in 500ml of 5%
dextrose) administered at 2-20mg/kg/min and titrated to maintain
systolic blood pressure greater than 90 mm Hg, should be
administered if epinephrine injections and volume expansion
fail to alleviate hypotension.74 Dopamine will usually increase
blood pressure while maintaining or enhancing blood flow to
the renal and splanchnic circulation. In cases of intractable hypo-
tension, transfer of the patient to a hospital, with an appropriate
critical care environment, should be performed as soon as
possible.
It has been shown that a dose of dopamine > 10 mg/kg/min is
usually required to produce peripheral vasoconstriction which
would be required to maintain systolic blood pressure. After
promising results in various animal models for cardiopulmonary
resuscitation, vasopressin has been investigated for potential
benefit in cardiac arrest in humans.75-77 In addition, there is one
report evaluating the effectiveness of vasopressin on hypotension
in two adults who experienced insect sting anaphylaxis and one
report of a patient who received vasopressin after anaphylaxis
to a drug.78-79been performed to evaluate the potential efficacy of vasopressin
in anaphylaxis, alone or in combination with epinephrine.
H1 AND H2 ANTIHISTAMINES
Antihistamines are considered supportive therapy and do not
replace epinephrine. Antihistamines are second line drugs that
can be given after epinephrine administration since they may be
useful for control of cutaneous and cardiovascular manifestations.
The salient features regarding use of antihistamines are:
d Diphenhydramine, an H1 antagonist, may be given IM or
by slow intravenous infusion in a dose of 25 to 50 mg in
adults, and 1 mg/kg up to 50 mg in children. Indirect
evidence supports the parenteral administration of di-
phenhdramine and hydroxyzine. Oral diphenhydramine
as well as other oral first or second generation H1 antihis-
tamines can also be used. There is no direct outcome data
regarding the effectiveness of any antihistamine in
anaphylaxis.81
d An H2 antagonist added to the H1 antagonist may be
helpful in the management of anaphylaxis.19,81-87. Paren-
teral ranitidine can be considered in a dose of 1 mg/kg in
adults, and 12.5 to 50 mg in children. Since time to max-
imum serum concentration (Cmax) is approximately the
same for intravenous and intramuscular administration,
either route can be considered. If intravenous adminis-
tration is chosen, the drug should be infused over 10 to
15 minutes. It may also be diluted in 5% dextrose to a vol-
ume of 20 ml and injected over 5 minutes.
CORTICOSTEROIDS
Glucocorticosteroids have not been shown to be effective for
the acute treatment of anaphylaxis but could, theoretically,
prevent protracted anaphylaxis. There is no conclusive evidence
that the administration of corticosteroids prevents a biphasic
response.88
OTHER PROPOSED THERAPIES FOR ANAPHYLAXIS
Several other therapeutic agents have been proposed for use in
anaphylaxis. However, there is no high quality evidence that
supports these agents, and existing data are too limited for
consensus opinions to be reached.
d Leukotriene modifiers:
At this time there are no data documenting the efficacy of
leukotriene modifiers in the treatment of anaphylaxis or
in its prevention. In addition, at this time, the only avail-
able route of administration is oral and therefore the
onset of action of such agents in anaphylaxis would not
be optimal.
d Tranexamic acid has been used to treat anaphylactic ep-
isodes associated with disseminated intravascular coagu-
lation, however, it is not available in the United States.89
d Nitric oxide synthesis inhibition via methylene blue has
been reported, in case reports, to be helpful in the treat-
ment of hypotension occurring during anaphylaxis.
There are no controlled studies, however, involving the
use of this agent in anaphylaxis.90
OBSERVATION AND SUBSEQUENT FOLLOW-UP
Biphasic anaphylaxis occurs in 1% to 23% of episodes, and
17. As is the case of anaphylaxis following other agents,
asthma is a risk factor for more severe food-induced
anaphylaxis. (C)
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resolution of the initial phase5. However, observation periods
must be individualized since there are no consisently reliable pre-
dictors of biphasic or protracted anaphylaxis based on initial clin-
ical presentation.
Follow-up of patients who have experienced anaphylaxis must
be individualized and based on such factors as clinical scenario
and distance from patient’s home to closest emergency facility.
At the time of discharge from medical supervision, patients
should be provided with autoinjectible epinephrine and instructed
in its use. In circumstances where an allergist/immunologist is not
already involved, it is strongly recommended that consultation
with an allergist/immunologist be obtained.
An action plan is an important component of the follow-up of
patients who have experienced anaphylaxis. Available resources
may be an important consideration in determining the treatment
plan that is appropriate for the setting in which the physician
practices.91-93 Examples of written action plans can be down-
loaded over the Internet (e.g., American Academy of Allergy,
Asthma, and Immunology (www.aaaai.org/members/resources/
anaphylaxis_toolkit/action_plan.pdf) [Spanish language versions
of the following AAAAI anaphylaxis materials are available: the
AAAAI Anaphylaxis Emergency Action Plan, Killer Allergy in-
formation page, AAAAI Anaphylaxis Tips to Remember bro-
chure, and AAAAI Anaphylaxis Easy Reader page.]; Food
Allergy and Anaphylaxis network [English language version:
www.foodallergy.org/actionplan.pdf; Spanish language version:
www.foodallergy.org/spanishaction.pdf; www.foodallergy.org/
school/SchoolGuidelines.pdf]).
ANALYSIS OF ANAPHYLAXIS OUTCOMES AND
PROCEDURES
Following treatment for any episode of acute anaphylaxis, the
clinician should consider an analysis of the event and the possible
precipitating cause, particularly with respect to those steps that
could be done to prevent future episodes. (See Section on
Prevention of Anaphylaxis.) The clinical staff can also critique
the approach taken tomanage anaphylaxis after each episodewith
regard to what worked well and what needs improvement.
ANAPHYLAXIS TO FOODS
Summary Statements14. Food is the most common cause of anaphylaxis in the
outpatient setting and food allergens account for 30%
of fatal cases of anaphylaxis. (D)
15. The most commonly implicated foods responsible for
food-induced anaphylaxis include: peanuts, tree nuts,
fish, shellfish, cow’s milk, soy and egg. In addition ses-
ame seed has recently been identified as a significant
cause of food-induced anaphylaxis. (C)
16. Common themes associated with fatal food anaphylaxis
include: reactions commonly involved peanuts and tree
nuts; cutaneous and respiratory symptoms are fre-
quently observed; victims are typically teenagers and
young adults; patients have a prior history of food al-
lergy and asthma; and there is a failure to promptly ad-
minister epinephrine. (C)18. Biphasic anaphylactic reactions can occur in up to 25%
of fatal and near-fatal food reactions. (C)
19. Serum tryptase measurements may not be elevated in
cases of food-induced
20. The rapid use of injectible epinephrine has been shown
to be effective in the initial management of food-induced
anaphylaxis but subsequent doses may be needed. (C)
21. Patients who experience anaphylaxis should be ob-
served for longer periods if they have experienced
food-induced anaphylaxis. (C)
22. Food-dependant, exercise-induced anaphylaxis is a
unique clinical syndrome in which anaphylaxis occurs
within a few hours of specific food ingestion or any
meal, and exercise. (C)
23. Patients with food allergy should pay close attention to
food advisory labeling (e.g. ‘‘may contain’’), which have
become more prevalent. (C)
Foods are arguably the most common cause of anaphylaxis.94,95
The prevalence of food-induced anaphylaxis is increasing. The
most frequently incriminated foods are peanuts, tree nuts, fish,
and shellfish but other foods, such as sesame seeds, have become
increasingly important as causes of food-induced anaphylaxis.95,96
Reactions can occur after the first known exposure.97
Common themes have emerged regarding fatal reactions to
foods. Most victims are teenagers or young adults who typically
have a known food allergy. Asthma is a risk factor for mortality,
and in many instances there has been failure to promptly
administer epinephrine. Life-threatening reactions may present
without any cutaneous manifestations, and can be characterized
by only respiratory and/or cardiovascular symptoms.88
Biphasic reactions appear to be more common in food-induced
anaphylaxis than in anaphylaxis related to other causes, and have
been reported in up to 25% of fatal or near fatal reactions.88
Serum tryptase may be less frequently elevated distinguishing
it from other causes. Serum tryptase may be less frequently
elevated in cases of food-induced anaphylaxis than anaphylaxis
produced by parenteral administration of allergen.97
All patients with food-induced anaphylaxis should be prescribed
autoinjectible epinephrine and instructed in its use. It has been well
established that epinephrine is underutilized by individuals with
food-induced anaphylactic events.94 Although it is rare for patients
with oral allergy syndrome to develop anaphylaxis, they may be at
increased risk, based on reports of patients who have had anaphy-
lactic reactions to foods after previously manifesting only the oral
allergy syndrome.98 Therefore, consideration could be given to
prescribing such patients autoinjectible epinephrine.
At this time, there is no means for preventing food-induced
anaphylaxis except for avoidance of those foods that are known or
suspected of causing a reaction in a given patient.
Patients with food allergy should be instructed in how to
properly interpret food labels and to avoid foods if the contents
are not known.
Natural Rubber Latex (NRL)-Induced Anaphylaxis
Summary Statements
24. There are three groups that are at high risk of reaction
to latex: health care workers; children with spina bifida
and genitourinary abnormalities; and workers with oc-
cupational exposure to latex. (C)
25. In vitro assays for IgE to NRL are typically recommen-
intraoperative anaphylaxis may differ considerably from anaphy-
laxis not associated with surgical procedures. While cutaneous,
hypotensive and respiratory events occur in both, hypotensive
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due to their suboptimal diagnostic predictive value,
positive and negative results must be interpreted based
on the history. If the test is positive with a high clinical
likelihood, latex sensitivity would be reasonable to pur-
sue. In contrast, if the test is negative with a high clinical
likelihood, latex sensitivity still must be considered. (C)
26. A standardized commercial skin test reagent for NRL is
not available in the United States. In this regard, aller-
gists have prepared NRL extracts from gloves to use for
clinical testing. It should be noted, however, that such
extracts prepared from gloves demonstrate
tremendous variability in content of NRL allergen.
Nevertheless, skin prick test with NRL extract to iden-
tify IgE-mediated sensitivity should be considered if pa-
tients are members of high risk groups or have a clinical
likelihood of NRL allergy and have negative in vitro
tests. (C)
27. Patients with spina bifida (regardless of a history of NRL
allergy) and patients with a positive history of NRL al-
lergy ideally should have all medical-surgical-dental
procedures performed in a NRL safe environment. (D)
28. A NRL-safe environment is an environment in which no
NRL gloves are used in the room or surgical suite and
there is limited NRL accessories (catheters, adhesives,
tourniquets, and anesthesia equipment or devices)
which come in contact with the patient. (D)
29. In health care settings, general use of NRL gloves with
negligible allergen content, powder-free NRL gloves,
and nonlatex gloves and medical articles should be con-
sidered in an effort to minimize patient exposure to latex.
Such an approach can diminish NRL sensitization of
health care workers and patients and reduce the risk of
reactions to NRL in previously sensitized individuals. (D)
30. Patients with a diagnosis of NRL allergy by history and/
or skin testing can wear a medical identification bracelet,
carry a medical identification card, or both. If patients
have a history of anaphylaxis to NRL, it is important
for them to carry auto-injectible epinephrine. (D)
Latex sensitization is due to IgE-mediated reactivity to any
number of antigens from Hevea brasiliensis, the source of latex.
Sensitization occurs in up to 12 percent of health care workers,
up to 75 percent of patients with spina bifida and in patients un-
dergoing multiple surgical procedures.99-101 Sporadic cases of la-
tex induced anaphylaxis have been reported due to hair glue and
plastic balls with latex pit.102 Atopic and latex-exposed individ-
uals are also at higher risk. Individuals can be sensitized to minor
or major antigens. At least 240 separate polypeptides can be dis-
cerned by two dimensional electrophoresis. Less than 25% of
these have been shown to react with IgE from patients with latex
allergy. They tend to cluster into groups of 11 proteins.103 With
exposure, sensitized individuals may develop urticaria, angioe-
dema, allergic rhinitis, asthma and anaphylaxis. Latex-induced
anaphylaxis from powdered latex gloves, as well as other sources,
may present in the operating room in patients, surgeons, nurses or
anesthesiologists (Table E5). Latex has been reported to account
for up to 17% of intraoperative anaphylaxis.103 The features ofcardiovascular collapse is a feature of reactions to latex during
surgerywhile dizziness or syncope is found largely in anaphylaxis
induced by non-surgical procedures.104 Latex-induced anaphy-
laxis is due to IgE-mediated mechanisms. Thus, in conjunction
with a careful history and physical examination, detection of
IgE to latex can be helpful in the diagnosis. Unfortunately, no
standardized skin test reagent for latex is available in the United
States, but ‘‘homemade’’ skin test preparations may be made from
latex gloves. It is clear, however, that such ‘‘homemade’’ extracts
are not standardized, and the amount of latex allergenwithin these
extracts is highly variable. For diagnostic purposes, in-vitro tests
for latex-specific IgE are available although the sensitivity of
these tests may vary (see Allergy Diagnostic Testing; An Updated
Practice Parameter). Due to the suboptimal diagnostic utility of
these tests, results should be correlated with the clinical history.
If the test is positive with a high clinical likelihood, latex sensitiv-
ity would be reasonable to presume. In contrast, if the test is neg-
ative with a high clinical likelihood, one cannot rule out latex
sensitivity. In vitro tests have highly variable sensitivity and spec-
ificity characteristics. The sensitivity has been found to be as low
as 50% and as high as 100%.104,105
Latex-induced anaphylaxis may occur in a variety of situations,
all involving direct contact with latex, usually gloves, or instru-
ments, or with aerosolization of latex antigen adherent to the
cornstarch powder of latex gloves. Thus, latex reactions can occur
during operative procedures, when gloves are donned. Latex
reactions may occur immediately with latex contact or may be
delayed from 30 to 60 minutes. Intraoperative latex anaphylaxis
may be related to the administration of drug through a latex port
prior to surgery, or during the surgical procedure itself. Latex
reactions have also been reported to occur during dental proce-
dures from latex gloves or dams, during obstetrical or gyneco-
logic examinations and during latex condom use. Spina bifida
patients are potentially at risk during each surgical procedure
because of the numbers of procedures they undergo.
Avoidance is extremely important. For the sensitized health
care worker, latex gloves should not be worn and the worker’s
colleagues should wear non-powdered latex gloves or non-latex
gloves. The workplace should be ‘‘latex safe’’ with all non-glove
latex devices replaced by non-latex devices. A ‘‘latex free’’
emergency cart (Table E6) should be available to treat reactions.
Rubber stoppered vials should be avoided.
Settings in which latex avoidance precautions should be
instituted in latex-sensitive patients might include surgical pro-
cedures, obstetrical or gynecologic examinations, or dental care.
The surgical room, dental area or examination area should be free
of latex devices and no latex gloves should be worn. Appropriate
emergency medications should be available for treatment, should
a reaction occur.
ANAPHYLAXIS DURING GENERAL ANESTHESIA,
THE INTRA-OPERATIVE PERIOD, AND THE POST-
OPERATIVE PERIOD
Summary Statements
31. The incidence of anaphylaxis during anesthesia has been
reported to range from 1 in 4000 to 1 in 25,000. Anaphy-
laxis during anesthesia can present as cardiovascular
collapse, airway obstruction, and/or skin manifesta-
tions. C
32. It can be difficult to differentiate between immune and
life-threatening reactions usually are IgE- mediated.117 The ter-
tiary or quaternary ammonium group, common to all muscle relax-
ants, is likely the immunodominant determinant recognized by
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cologic effects from the variety of medications adminis-
tered during general anesthesia. In addition, cutaneous
manifestations of anaphylaxis are less likely to be ap-
parent when anaphylaxis occurs in this setting. B
33. The evaluation of IgE-mediated reactions to medica-
tions used during anesthesia can include skin testing
to a variety of anesthetic agents. B
34. The management of anaphylactic reactions that occur
during general anesthesia is similar to the management
of anaphylaxis in other situations. B
35. Thiopental allergy has been documented by skin tests. B
36. Neuromuscular blocking agents, such as succinylcho-
line, can cause nonimmunologic histamine release, but
there have also been reports of IgE-mediated reactions
in some patients. B
37. Reactions to opioid analgesics are usually caused by di-
rect mast cell–mediator release rather than IgE-
dependent mechanisms. B
38. Antibiotics that are administered perioperatively can
cause immunologic or nonimmunologic reactions. B
39. Protamine can cause severe systemic reactions through
IgE-mediated or nonimmunologic mechanisms. B
40. Blood transfusions can elicit a variety of systemic reac-
tions, some of which might be IgE-mediated or medi-
ated through other immunologic mechanisms. B
41. Methylmethacrylate (bone cement) has been associated
with hypotension and various systemic reactions, al-
though no IgE mechanism has been documented.C
Diagnosis. Diagnosis of anaphylaxis during general anesthe-
sia and post-operatively is hampered by the following:
d The diagnosis of anaphylaxis depends in large part on the pa-
tient’s ability to describe the event, and the patient cannot de-
scribe symptoms because they are unconscious or not fully
conscious.
d Skin manifestations are an important and frequent indicator
of anaphylaxis and skin manifestations may be masked by
surgical drapes.
d Skin manifestations are less common than they are when an-
aphylaxis occurs in other settings.
d Cardiovascular collapse may be the sole manifestation of an-
aphylaxis and may be confused with other causes of cardio-
vascular collapse in this setting.
d Bradycardia occurs more often in this setting than in other
settings of anaphylaxis and health care providers are more
likely to think of anaphylaxis if the patient develops
tachycardia.
The causes of anaphylaxis in this setting are varied, as are the
mechanisms responsible for the reaction (Table E7). The most
common cause of anaphylaxis during general anesthesia or post-
operatively is neuromuscular blocking agents (muscle relaxants),
which are responsible for sixty to seventy percent of episodes of
anaphylaxis occuring during this period.106-116
Most of the muscle relaxants cause direct release of mast cell
histamine without the requirement for specific antibody. However,IgE.118 The antigenicity of the shared ammonium structures may
be responsible for cross-reactivity among the muscle relaxants.
Cross-reactivity occurs most consistently between pancuronium
and vecuronium.119 Cross-reactions also may occur between mus-
cle relaxants and other classes of pharmaceuticals, based upon in
vitro inhibition of specific-IgE binding to the muscle relaxants.
Agents that potentially cross-react with muscle relaxants include:
acetylcholine, choline, morphine, neostigmine, and pentolinium.
Cross-inhibition suggests that previous exposure to these non-
anesthetic drugs may sensitize individuals to muscle-relaxing
agents, resulting in reactions among patients without prior anesthe-
sia.120 Three out of four cases of anaphylaxis to muscle relaxants
occur in females, suggesting cross-reactivity with ammonium
compounds in personal care products.121 Skin testing may be use-
ful to determine the safest alternative for subsequent anesthesia fol-
lowing a suspected reaction, recognizing that nonimmunologic
reactions are not identified by this diagnostic method122,123 Skin
testing is not recommended for preanesthetic screening of subjects
without a history of suspected reactions.124
Antibiotics frequently are administered before, during, or
immediately after anesthesia and surgery. Allergic reactions to
antibiotics, particularly anaphylaxis, may occur during the peri-
operative period. The antibiotics most commonly implicated in
reactions during this period are b- lactam antibiotics and
vancomycin.125
Vancomycin is a glycopeptide antibiotic selectively used for
treatment of resistant organisms and for use in individuals with
penicillin allergy. Administration, especially when it is rapid,
may result in life-threatening, non-IgE-mediated anaphy-
laxis.126-128 Direct histamine release and direct myocardial
depression partially expain this phenomenon.129 These nonim-
munologic reactions to vancomycin can be reduced or eliminated
by administering this drug as a dilute solution, dissolved in at
least 200 mL, and infused over at least a 2 hour period. IgE-
mediated anaphylaxis to vancomycin is much less common.
Skin testing with a concentration of 0.15 mg/mL or less has
been reported, but the reliability of this testing is less than with
penicillin skin testing.130,131 Nevertheless, skin testing with van-
comycin may have some value in distinguishing rate-related
adverse events from anaphylaxis.
Dextran and hydroxyethyl starch (HES), large-molecular–
weight polysaccharides, may be used as a non-blood, high-
oncotic fluid replacement during surgery. These agents are
infrequently associated with adverse reactions and anaphylaxis.
Estimates of reaction rates are 0.008% to 0.08% for dextran and
0.08% for HES.132 Specific antibodies can be detected to dextran
or HES, but their clinical significance is unknown.133,134 Confir-
mation of dextran or HES as the cause of an adverse reaction is
limited by the absence of validated serologic or skin tests. Skin-
test reactivity to undiluted solutions has been described but is
of unknown predictive value.121 Case reports also describe
systemic reactions to albumin, but the mechanism for such ad-
verse effects is not known.119
Intravenous drugs used for anesthetic induction can cause peri-
operative anaphylaxis. More than 290 cases of anaphylaxis are re-
ported in the literature from the use of barbiturates, especially
thiopental. However, the reaction rate with barbiturates is only
1:25,000, with the reported occurrence of reactions reflecting
the common use of these compounds.117 Women are three times
more likely to have reactions from thiopental than men.121,124
Most of the adverse reactions with barbiturates, particularly thio-
The management of anaphylaxis in the peri-operative period is
similar to the management of anaphylaxis in other situations. Re-
ports that arginine vasopressin may be superior to epinephrine re-
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histamine-releasing activity also occurs.121,135-137 The impor-
tance of immunologic cross-reactivity is unknown. Skin testing
may be clinically useful, but the concentration of drug testing
must be less than the concentration that result in irritation. See Ta-
ble E8 for the concentration of anesthetic agents that has been rec-
ommended for intradermal skin testing.122,123
Propofol is a nonbarbiturate induction agent that is potentially
useful if sensitivity to barbiturates is a concern.138 IgE-mediated
reactions from propofol may occur139,140, however, most adverse
reactions to propofol are non-immunologic.142 Propofol may di-
rectly stimulate histamine release, and this effect may be greater
when administered with muscle relaxants.142
Narcotics used in peri-operative period are a common cause of
flushing and urticaria following intravenous administration. Ana-
phylaxis, in contrast, is very rare.143,144 Dermal mast cells express
opioid receptors that bind to the narcotic and stimulate histamine
release. Other populations of mast cells do not express this recep-
tor. Cutaneous flushing and hives often occur after intravenous
morphine administration, but with rare exceptions, the amount of
histamine release does not result in hypotension or broncho-
spasm.145 Reducing the rate of opioid administration usually limits
the severity of these reactions. Fentanyl does not directly stimulate
histamine release by way of the mast-cell opioid receptor.145 There
are reports of anaphylaxis tomorphine and fentanyl.146 The predic-
tive value of skin testing with morphine has not been determined.
Intravenous protamine, an agent used to reverse heparin antico-
agulation, may cause both anaphylactic and anaphylactoid reac-
tions; the latter is characterized by increases in pulmonary
blood pressure. Potential pathophysiologic mechanisms are nu-
merous and varied.147-151 A case control study (multivariate
odds ratio [95% confidence interval]) showed that previous neu-
tral protamine Hagedorn insulin use (8.18 [2.08, 32.2]), fish al-
lergy (24.5 [1.24, 482.3]), and other medication allergy (2.97
[1.25, 7.07]) are independent risk factors for anaphylaxis150.
The authors estimate that up to 39% of cardiopulmonary bypass
patients have one or more of these risk factors. Allergy to fish
has not been conclusively shown to be associated with protamine
allergy.155,156 Skin prick tests and specific IgE antibodies have not
been demonstrated to be clinically useful in the diagnosis of hy-
persensitivity to protamine.
Although benzodiazepines are frequently used peri-operatively,
adverse reactions are exceedingly rare. Themechanism of clinical
adverse reactions has not been studied. Specific IgE has not been
detected by skin tests or in-vitro tests.157,158
Local anesthetic agents readily induce cell-mediated immuno-
logic reactions when applied topically to the skin, but humoral
immune responses are rare. Adverse effects from local anesthetics
are not uncommon, but immunologically mediated reactions fol-
lowing parenteral administration are very unusual. Percutaneous
testing, followed by intracutaneous testing, usually is performed
with one or more local anesthetics. Dilutions of the anesthetics
may be considered for the initial testing if the history is highly
suggestive of anaphylaxis. Ideally anesthetic agents with and
without preservatives are used to determine if preservative sensi-
tivity, rather than anesthetic allergy, could be responsible for the
reaction. Local anesthetics without epinephrine are preferable if
the history is suggestive of an anxiety response.quire confirmation before any change in treatment
recommendations.159
The diagnosis of perioperative anaphylaxis is challenging be-
cause of the multiple drugs administered, concurrently or se-
quentially, and the effects of anesthesia itself. An elevated
serum tryptase level 1 to 6 hours after suspected anaphylaxis
suggests mast cell degranulation and supports the diagnosis of
anaphylaxis in the presence of a typical history and clinical
findings.22,25,160 Additional diagnostic testing for the agent re-
sponsible for mast cell degranulation, usually by measuring
specific-IgE, would be advisable if the serum tryptase were el-
evated. A normal tryptase level, however, does not exclude
anaphylaxis.
Testing for specific-IgE to a suspected, causal agent is not
recommended until several weeks after a reaction, because
transient decreases in measurable allergen specific-IgE may
occur after anaphylaxis. Skin tests with agents used during the
peri-operative period may be difficult to interpret because many
drugs can cause direct mast-cell histamine release in the absence
of specific-IgE. Nonetheless, skin testing has been shown to be
valuable in evaluating anaphylaxis to barbiturates, streptokinase,
penicillin, insulin, local anesthetic, and latex. In vitro testing for
specific IgE antibodies has been reported for muscle relaxants,
thiopental, morphine, propofol, and latex.
The prevention of peri-operative anaphylaxis is an elusive ideal
because of the rare occurrence of reactions, multiple pathophys-
iologic mechanisms (many of which are undefined), the limited
ability to test for sensitization and the limited ability to define
the risk of recurrence. A careful medical history that focuses on
previous adverse reactions is most important. A prior medication
reaction nonspecifically increases the possibility of adverse reac-
tions, and multiple previous medication reactions pose a greater
risk. Atopic individuals may be at increased risk because of either
an increased frequency of reactions or, more often, an increased
severity of reactions. Previous anesthetic-associated reactions
should be evaluated thoroughly, with specific testing if indicated.
IgA-deficient subjects should receive washed red blood cells and
not whole blood to avoid exposure to exogenous IgA. Intraoper-
ative antibiotics should be administered slowly with careful he-
modynamic monitoring. Drugs with histamine-releasing
properties (e.g., morphine, d-tubocurarine, vancomycin, quater-
nary muscle relaxants) should be administered as slowly as pos-
sible, particularly in subjects with asthma or cardiopulmonary
disease. Pretreatment regimens, as used for patients who have ex-
perienced anaphylactoid reactions to radiocontrast material, have
not been proven to prevent reactions, but may reduce the severity
of such reactions even if a non-IgE mediated mechanism is
suspected.
Peri-operative anaphylaxis, mediated by immunologic, non-
immunologic, or undefined mechanisms, is becoming more
common, probably because of more frequent use of anesthesia
and the increasing complexity of utilized drugs. Recognition and
immediate treatment are particularly important because anesthe-
tized patients are at greater risk for adverse outcomes caused by
the physiologic effects of anesthesia. Vigilance for the signs of
anaphylaxis and consideration of risk factors, with possible
modification of the agents used, will likely reduce the morbidity
and mortality associated with these reactions.
SEMINAL FLUID ANAPHYLAXIS
Summary Statements
urticaria; pelvic pain associated with uterine contractions; nasal
symptoms including rhinorrhea and sneezing; wheezing, dyspnea
and/or laryngeal edema; and, rarely, hypotension and syncope.
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been shown to be due to IgE-mediated sensitization to
seminal plasma proteins of varying molecular weight. C
43. Post-coital local reactions to human seminal plasma are
probably IgE-mediated based on successful response to
rapid seminal plasma desensitization. C
44. History of atopic disease is the most consistent risk fac-
tor for seminal fluid-induced anaphylaxis. C
45. The diagnosis of seminal plasma anaphylaxis may be
confirmed by skin testing with fresh whole human sem-
inal plasma or its fractions obtained from the male part-
ner. It is essential to exclude other underlying causes
such as allergens in natural rubber latex condoms, or
in drugs or foods passively transferred via seminal
plasma. D
46. Greater than 90% of the allergenic proteins range be-
tween 12 to 75 kd. Prostate specific antigen has been de-
monsrated to be a relevant allergen in some cases. C
47. Systemic and localized reactions to seminal plasma can
be prevented by correct use of condoms. Nevertheless,
in the event of barrier failure, sexual partners should
be prepared to treat acute anaphylaxis. C
48. Subcutaneous immunotherapy to properly prepared
fractions of seminal plasma collected from male part-
ners has been successful in preventing anaphylaxis to
seminal plasma. C
49. Successful intravaginal graded challenge with whole
seminal plasma of the male partner has been reported
in a few cases but the duration of protection is un-
known. This treatment approach may be considered
prior to pursuing desentization using relevant semimal
plasma protein fractions. C
50. Patients with seminal plasma allergy may be able to
conceive without undergoing desensitization, by artifi-
cial insemination with washed spermatozoa. C
Anaphylaxis due to coital exposure to human seminal fluid is a
rare occurrence. Since the initial report in 1958,161 approximately
30 cases of seminal fluid induced anaphylaxis have been de-
scribed.162-164 All reactions have occurred in female patients dur-
ing or after sexual intercourse. The vast majority of such reactions
are caused by IgE-mediated sensitization to human seminal
plasma proteins with molecular weights ranging from 12-75
kD.165-167 In rare cases, spermatozoa have been identified as the
source of allergens inducing a cell-mediated reaction.168 Coital
anaphylaxis has also been attributed to exogenous allergens trans-
ferred via semen during sexual intercourse. Such unusual reac-
tions occur when a male partner ingests a food (e.g., walnuts)
or drug (e.g., penicillin) towhich there is established sensitization
in the female partner.169
Seminal plasma hypersensitivity is essentially a diagnosis by
exclusion. A detailed history is essential to rule out other causes,
such as sexually transmitted diseases, latex sensitivity, transfer of
food or drug proteins from the male sexual partner to the female
who may be sensitized to these agents or other contactants, such
as sanitary napkins. Anaphylaxis to seminal plasma protein
begins within seconds to minutes after ejaculation and presents
with a range of symptoms including: diffuse pruritus andThe effective prevention of reactions by correct use of condoms is
a common feature.170 Failure of condoms to prevent anaphylaxis
suggests either incorrect condom technique or concurrent sensiti-
zation to latex.171 Localized vulvar and vaginal burning may oc-
cur as isolated symptoms or in conjunction with itching and
swelling following ejaculation.172 There is no evidence that local-
ized vaginal seminal plasma hypersensitivity increases the likeli-
hood of a future systemic reactions.
The most significant risk factor for seminal plasma protein
anaphylaxis is a history of allergic asthma or atopic dermatitis.163,
167,173 Anecdotal case reports of seminal fluid anaphylaxis have
occurred post-partum, after gynecologic surgery and following
injection of anti-Rh immune globulin.163 It has not been estab-
lished if such events are coincidental or could somehowmodulate
immune tolerance resulting in sensitization to seminal fluid pro-
teins. Reactions have also been observed in women whose male
partners have recently undergone prostatectomy or vasectomy.174
Anaphylactic events have been reported in women with multiple
previous sexual encounters or in others, after the first coital act.163
Post-coital allergic reactions are not specific to one partner and al-
most always recur with different male partners. Surveys have in-
dicated that most patients with seminal plasma hypersensitivity
are not promiscuous, typically having reported a history of less
than two sexual partners.163
The diagnosis must be confirmed by in vivo and/or in vitro dem-
onstration of sensitization to seminal fluid proteins.165 Based on
available data, in vitro tests (e.g., RAST, ELISA) of serum spe-
cific IgE appear to be less sensitive than skin testing.163
A negative serologic test for seminal plasma specific IgE does
not exclude sensitization. Therefore, skin prick testing with whole
human seminal plasma from the male partner is recommended for
initial screening of suspect cases. Prior to skin testing, the male
donor must be screened for viral hepatitis, syphilis and HIV infec-
tion and if there is evidence of infection, skin testing should not be
performed.165,167,168
Percutaneous or intracutaneous responses to relevant seminal
plasma protein fractions have been detected in all reported cases
of anaphylaxis. The presence of positive serologic specific IgE
antibodies to these fractions and specific skin tests to the same
fractions is highly predictive of a successful treatment outcome
with seminal plasma protein desensitization.175
Consideration must be given to the psychologic impact of this
condition on the patient, his/her partner and the future of their
relationship. Couples should be informed that successful preg-
nancies have been achieved after artificial insemination with
sperm washed free of seminal plasma or by in utero fertiliza-
tion.174 Once the diagnosis is suspected, the patient must be ad-
vised to avoid coital exposure to seminal fluid. This can be
achieved by either temporary cessation of intercourse or with
the correct use of latex condoms. Coitus interruptus is often not
successful due to potential leakage of seminal fluid during inter-
course, which can result in a reaction and is therefore discour-
aged. Condoms made from lambskin or a plastic polymer can
be substituted in the latex-sensitive patient. If anaphylaxis is
caused by seminal transfer of exogenous allergens, the male part-
ner should avoid the causative food or drug prior to engaging in
sexual intercourse.168,169 It is essential that patients and their
partners be trained in the emergency use of autoinjectable
epinephrine. Although there are reports of successful use of pre-
coital treatment with antihistamines or intravaginal cromolyn
sodium, these options have generally been ineffective in the pre-
should be performed. The diagnosis is usually made
based upon history and exclusion of other disorders.
Exercise challenge testing does not consistently repro-
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There are couples for whom abstinence, regular use of
condoms, or artificial insemination to achieve pregnancy are
unacceptable options. In such situations, immunotherapy with
seminal plasma fractions of the male partner should be consid-
ered. This procedure should only be performed in specialized
centers and under the supervision of experienced
physicians.165-168,170,176
Successful intravaginal graded challenges have been reported
in women diagnosed with human seminal plasma anaphylaxis
confirmed by skin prick test reactivity to whole seminal
plasma.177-182 As with parenteral desensitization protocols, fre-
quent intercourse (two to three times per week) is required to
maintain the desensitized state. The efficacy of intravaginal
graded challenge is based entirely on anecdotal reports. More-
over, the duration of the protective effect is unknown. Graded in-
travaginal challenges have been less effective in women with
localized seminal plasma hypersensitivity reactions.183
It is very important to inform women with this condition that
although seminal plasma hypersensitivity can cause significant
stress, it has no impact on their ability to get pregnant as it has not
been associated with infertility.181,183
In summary, the following techniques can be utilized in the
management of patients with seminal fluid induced anaphylaxis:
d Barrier condoms can be successful tools of management. In
the latex-allergic patient, polyurethane condoms can be used.
d In cases due to the transfer of exogenous allergens, the male
partner should avoid the food or drug in question.
d The patient and spouse should be suppliedwith and trained in
the use of an automatic epinephrine injector.
d When these therapies are not effective or are unacceptable,
immunotherapy can be instituted. Couples should be in-
formed that successful pregnancies have occurred in patients
with this problem. There is no association between seminal
fluid hypersensitivity and infertility.
EXERCISE-INDUCED ANAPHYLAXIS
Summary Statements
51. Exercise is the immediate trigger for the development
of symptoms in exercise induced anaphylaxis (EIA).
Typical symptoms include extreme fatigue, warmth,
flushing, pruritus, and urticaria, occasionally progress-
ing to angioedema, wheezing, upper airway obstruc-
tion, and collapse. A
52. The pathophysiologic events during exercise that pre-
cipitate symptoms are not known, although promising
lines of research exist. C
53. Some patients experience symptoms only if other con-
tributing factors or ‘‘co-triggers’’ are present in associ-
ation with exercise. These co-triggers include ingestion
of specific foods, or in some patients ingestion of any
food, non-steroidal antiinflammatory drugs, and high
pollen levels. C
54. The clinical history should focus on identification of
these possible co-triggers. Evaluation for sensitization
to food allergens, particularly grains and seafood,duce symptoms. C
55. All patients with exercise-induced anaphylaxis must be
advised to stop exercising immediately at the first sign
of symptoms because continued exertion causes the at-
tacks to worsen. In addition, all patients should carry
epinephrine auto injectors and exercise with a partner
who can recognize symptoms and administer epineph-
rine if necessary. D
56. Prophylactic medications are not effective for prevent-
ing attacks in the majority of patients, although a small
subset does appear to benefit from daily administration
of H1 antihistamines. D
57. The prognosis of patients with exercise-induced ana-
phylaxis is generally favorable, although at least one fa-
tality has been reported. Most patients experience
fewer and less severe attacks over time. It is unclear if
this is the result of trigger avoidance or a change in
the underlying condition. C
Exercise-induced anaphylaxis (EIAn) is characterized by symp-
tomsofmast cellmediator release in the setting of physical exertion.
Typical early signs and symptomsbegin a fewminutes into exercise,
and include diffuse warmth, flushing, pruritus, urticaria, and
fatigue.184,185 If exercise continues, there may be progression to
angioedema of the face and extremities, gastrointestinal symptoms,
laryngeal edema, hypotension, or collapse.Wheezing can occur, al-
though it is less common than other symptoms. Some patients expe-
rience disabling headache that persists for several days after an
episode.185 Attacks occur sporadically and unpredictably, even
though most patients with this disorder exercise regularly.
Vigorous exercises, such as jogging, racquet sports, dancing,
and aerobics, are most often implicated, although lower levels of
exertion, such as brisk walking or yard work, are capable of
triggering attacks in some patients.186 Cessation of exercise usu-
ally results in improvement or resolution of symptoms, although,
patients often do not instinctively stop exercising when they first
experience symptoms. Instead, many try to run for help or sprint
home, and this precipitates a dramatic worsening of symptoms.
Once the patient either stops exercise or receives treatment, symp-
toms may dissipate rapidly or last for several hours. It is not
known how often this disorder results in fatal anaphylaxis, al-
though at least one death has been reported.187 Such events are
likely underdiagnosed and misdiagnosed, as with other causes
of fatal anaphylaxis.
Many patients require the presence of one or more other factors
in order to develop symptoms upon exercise. Reported ‘‘co-
triggers’’ include the ingestion of specific foods,188 the ingestion
of any solid food, non-steroidal anti-inflammatory drugs
(NSAIDs),186,189 alcoholic beverages, menstruation,6 or, seasonal
pollen exposure in pollen-sensitized patients.186 Typically, each
trigger is tolerated if there is no association with the other trigger,
e.g., patients with food as a co-trigger can eat the food without
symptoms or exercise without symptoms, although if they eat
the food and then exercise they will develop anaphylaxis.
In most cases, exposure to the co-trigger occurs first, followed
by exercise, with the latter triggering symptoms. Ingestion of
NSAIDs may precede exercise by hours to a day, whereas food or
alcohol ingestion typically has occurred within 4 to 6 hours before
exercise. The foods most commonly implicated are wheat, other
grains, nuts, and seafood, although a wide variety of foods have
been reported.188,190
The management of EIAn must be individualized, depending
upon the severity of symptoms, the presence of co-triggers, and
the patient’s desire to continue exercise. The patient must carry or
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EIAn among Japanese adolescents to be approximately 0.03
percent, with no clear gender preference.191 The prevalence of pa-
tients with purely exercise-triggered anaphylaxis, relative to those
who require exercise plus one or more cofactors, is not known, al-
though food-dependent anaphylaxis has been reported more
often.192
The pathophysiology of EIAn is not well-understood, although
there is evidence that it is a mast cell-mediated disorder. Skin
biopsies demonstrating degranulation of dermal mast cells fol-
lowing attacks,193 and transient elevations in plasma hista-
mine194,195 and serum tryptase196 have been documented in
case reports. However, the precise trigger(s) for mast cell activa-
tion have not been conclusively identified, and the events during
exercise that may alter the activity of mast cells or other leuko-
cytes have not been defined.
The diagnosis of exercise-induced anaphylaxis is based upon a
meticulous clinical history, skin or in vitro testing for IgE-
mediated allergy, and occasionally, documentingmast cell activa-
tion if this can be determined in the minutes or hours following an
attack.
As part of the history, each episode that can be recounted by the
patient should be reviewed in detail, to discern if any co-triggers
were present. A careful skin examination for lesions of urticaria
pigmentosa and a baseline serum tryptase level can be performed
to evaluate for mastocytosis, which can present with anaphylaxis
upon exertion.
Skin testing for sensitization to foods and environmental
allergens helps to define each patient’s potential co-triggers. In
food dependent -EIAn, IgE-mediated allergy to precipitating
foods is usually, although not always demonstrable. Patients who
do not initially test positive to foods that appear by history to be
co-triggers, may over time develop positive skin tests to suspected
food. Thus, if the history suggests a food co-trigger but testing is
negative, repeat testing over time may be useful.
The diagnosis of EIAn can be confirmed by eliciting symptoms
with treadmill testing. However, symptoms are difficult to repro-
duce.192,197 The differential diagnosis includes arrhythmias and
other cardiovascular events, but such events do not include pruri-
tus, urticaria, angioedema, or upper airway obstruction. Exercise-
induced bronchoconstriction presents with symptoms that are
limited to the airways. Exercise-associated gastroesophageal re-
flux could mimic mild symptoms of EIAn, although, urticaria
and/or pruritus are not observed.
Cholinergic urticaria, a physical urticaria usually limited to the
skin, can mimic the early cutaneous symptoms of EIAn. Cholin-
ergic urticaria is characterized by initially punctate (1 to 3 mm in
diameter) wheals with surrounding erythema of the affected skin.
Cholinergic urticaria is elicited by raising the core body temper-
ature, such as with a sauna or hot bath, very strong emotion, or
very spicy food and can be discerned with a careful history and
confirmed with passive warming. A minority of patients with
EIAn develop punctate urticaria,198 although most have larger
wheals (10 to 15mm in diameter). Patients with punctate urticaria
who develop symptoms in extracutaneous organs should be con-
sidered to have EIAn. Exercise is necessary to elicit the symptoms
of EIAn; passively raising the core body temperature should not
elicit symptoms in such patients.199have immediate access to autoinjectible epinephrine whenever
they exercise. Patients with EIAn should exercisewith a partner or
in a supervised setting at all times. The companion should be
educated about the condition and be capable of administering
epinephrine. Patients must be vigilant for early signs of EIAn
(e.g., flushing, pruritus) and stop exercise immediately if these
develop. It is imperative that patients understand the importance
of immediately stopping exercise at the first sign of symptoms.
For patients with identifiable co-triggers, avoidance of these
factors may allow them to resume exercise safely. For example,
patients who demonstrate sensitization to a food should avoid that
food completely if it is not an integral part of the diet. Foods that
are essential to the diet should not be eaten during the 6 hours
prior to exercise.
Pharmacologic therapy cannot be relied upon to prevent EIAn.
Oral H1 antihistamines, corticosteroids, oral cromolyn so-
dium,200 H2 antihistamines, or omalizumab, have not been eval-
uated in controlled studies, and/or have not been shown to be
consistently effective. H2 antihistamines, specifically in patients
with food dependent -EIAn, should be avoided because there is
preliminary evidence that H2 antihistamines may interfere with
normal digestion of food allergens and therefore could augment
a reaction.201-203
Most patients with EIAn report fewer attacks over time. Much
of this improvement may be attributable to modifications in
exercise habits and recognition of co-triggers. A questionnaire
administered to 279 patients, with EIAn persisting for longer than
10 years; found that the average number of episodes per year
decreased from 14.5 at the time of diagnosis, to 8.3 in the year of
the study. Patients reported avoiding exercise during extremely
hot, cold, or humid weather conditions, during pollen season
(pollen-allergic patients), after eating, and after taking
NSAIDS.186 Thus, with proper counseling and careful self-
monitoring, most patients are able to continue exercise and suffer
fewer attacks over time.
IDIOPATHIC ANAPHYLAXIS
Summary Statements58. The symptoms of idiopathic anaphylaxis are identical to
those of episodes related to known causes. C
59. Patients with idiopathic anaphylaxis should receive an
intensive evaluation, including a meticulous history to
rule out a definite cause of the events. C
60. There might be a need for specific laboratory studies to
exclude systemic disorders, such as indolent systemic
mastocytosis. This might include a measurement of se-
rum tryptase when the patient is asymptomatic, mea-
surement of total tryptase during or within 4 hours of
an acute episode, and the ratio of mature (b) tryptase
to total tryptase during an episode. To exclude heredi-
tary angiodema or acquired C1 inhibitor deficiency, a
C4 concentration can be obtained as it will be reduced
during or in the absence of severe angioedema in those
conditions but normal in idiopathic anaphylaxis. C
61. There might be a need for selective skin testing for detec-
tion of anti-food IgE antibodies when foods have been in-
gested within 2 hours of the onset of an episode. C
62 Empiric use of oral corticosteroids combined with H1
antagonists has been demonstrated to reduce the fre-
quency/severity of episodes. C
receiving daily or alternate day oral corticosteroids could in fact
have factitious anaphylaxis, globus hystericus, laryngopharyn-
geal reflux or undifferentiated somatoform idiopathic anaphy-
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nephrine, know the indications for self-administration,
and can carry information denoting their condition. C
The pathogenesis of idiopathic anaphylaxis is not understood.
Evidence of mast cell activation in idiopathic anaphylaxis
includes elevated urinary histamine,204,205 serum tryptase,
206,207 and mature (b) tryptase.200 Skin biopsies from patients
with idiopathic anaphylaxis reveal increased numbers of mast
cells compared to normal individuals but considerably less than
in non-lesional or lesional skin from patients with either urticaria
pigmentosa or indolent systemic mastocytosis.208 Lymphocyte
activation has been identified in blood samples obtained up to
24 hours after an episode, demonstrated by increases in
CD31HLA DR1 T cells and in activated CD191CD231 B
cells.209 Idiopathic anaphylaxis is a corticosteroid-responsive
condition based on empiric treatment with prednisone.7,210
The diagnosis of idiopathic anaphylaxis must be considered in
those cases of anaphylaxis for which neither a causative allergen
(e.g., medication, food, sting), inciting physical factor, or disease
state can be identified. Episodes occur primarily in adults or
adolescents with infrequent episodes in children. Almost one-half
of patients with idiopathic anaphylaxis have been found to be
atopic. They may also experience anaphylaxis from recognized
causes such as exercise, medication, or food.7,9
The diagnosis of idiopathic anaphylaxis remains one of exclu-
sion. Patients with idiopathic anaphylaxis should receive careful
evaluation for possible causes, with emphasis on the history of
events in the 3 hours prior to an episode. Selective skin testing
with foods (and if indicated to fresh food extracts) may be of
value. Indolent systemic mastocytosis must be excluded. Consis-
tently elevated serum tryptase levels suggest the presence of
indolent systemicmastocytosis since the serum tryptase (total and
a tryptase) will be elevated in the absence of episodes of
anaphylaxis. In contrast, serum tryptase levels will be normal in
quiescent idiopathic anaphylaxis. A bone marrow examination
may be indicated in patients with a diagnosis of idiopathic
anaphylaxis even in the absence or elevated tryptase levels if
salmon colored, hyperpigmented macules and papules consistent
with urticaria pigmentosa are found.211,212 The differential diag-
nosis of idiopathic anaphylaxis includes hereditary angioedema
or acquired C1 inhibitor deficiency. Some patients with idiopathic
anaphylaxis present with massive enlargement of the tongue and/
or life-threatening upper airway obstruction due to pharyngeal or
laryngeal angioedema, but their C4 concentration is not reduced.
The acute treatment of idiopathic anaphylaxis is the same as the
treatment for other forms of anaphylaxis. Prophylactic treatment
with oral prednisone at 60-100 mg daily in combination with H1
antagonists for 1-2 weeks followed by decreasing alternate day
prednisone over 3 months has resulted in reduced severity and
frequency of anaphylaxis. Such empiric treatment has been used
for patients with 6 or more episodes/year or 2 episodes in 2
months of idiopathic anaphylaxis.7,210 Patients should carry auto-
injectible epinephrine and be instructed in its use. Patients should
also carry identifying information such as by Medic Alert.
If a patient does not respond to prophylaxis for idiopathic
anaphylaxis, it is necessary to re-consider the diagnosis at each
visit. Patients who experience a greater number of episodes whenlaxis.212,213 The symptoms of idiopathic anaphylaxis are identical
to those of episodes related to known causes.
ANAPHYLAXIS TO ALLERGEN IMMUNOTHERAPY
EXTRACT (VACCINE)
Summary Statements
64. There is a small risk of near-fatal and fatal anaphylactic
reactions to allergen immunotherapy. C
65. Patients with asthma, particularly if poorly controlled,
are at higher risk for serious potentially life-threatening
anaphylaxis to allergen immunotherapy injections. C
66. It is unclear whether patients taking beta adrenergic
blocking agents are at increased risk of havng a seri-
ous systemic reaction to allergen immunotherapy
injections. B
67. Anaphylaxis in patients taking beta adrenergic block-
ing agents may be more difficult to treat. C
68. Allergen immunotherapy vaccines should be adminis-
tered only by health care professionals trained in the
recognition and treatment of anaphylaxis, only in
health care facilities with the proper equipment for
the treatment of anaphylaxis, and in clinics with policies
and procedures that minimize the risk of anaphylaxis. D
Based on surveys from 1945 to 2001, the rate of all systemic
reactions to subcutaneous allergen immunotherapy (AIT) injec-
tions has been estimated at 0.25-1.3%.214,215 Fatal anaphylaxis to
AIT injections occurs at an estimated rate of 1 in 2.5 million in-
jections216-219 and near-fatal anaphylactic reactions at a rate of
1 in every 1 million injections.220 Thus, although anaphylactic re-
actions to AIT are uncommon, physicians and patients should be
prepared for possible systemic reactions.
Numerous studies suggest that patients with asthma, particu-
larly poorly controlled asthma, are at higher risk for serious
systemic reactions to AIT injections.216,218,219,221, 222 The few pa-
tients who died from anaphylaxis after AIT injections were more
likely than patients surviving anaphylaxis to have previously re-
quired hospitalization for acute asthma.220,223 It is reasonable,
therefore, to assess asthma symptoms and measure peak expira-
tory flow rate before administering allergen injections to patients
with poorly controlled asthma.In addition, it is important to re-
member that a subset of asthmatics may poorly perceive their
level of control. Uncontrolled asthma must be stabilized before
AIT injections are administered.222
Although studies have reported that patients receiving AITwith
aeroallergens or Hymenoptera venom who are taking b-adrener-
gic blocking agents are at no greater risk of systemic reactions
than AIT treated patients not taking b -blockers, there is still
concern that these studies contain substantial bias and other
methodologic flaws.64,224 Certainly however, b-adrenergic
blockers may inhibit the beneficial therapeutic effects of epineph-
rine during anaphylaxis and enhance the need for subsequent
treatment in the hospital.225,226 Therefore, a cautious attitude
should be adopted toward the concomitant use of b-adrenergic
blockers and inhalant AIT.222 In patients with life-threatening
stinging insect hypersensitivity, the benefits of venom immuno-
therapy may outweigh any risk associated with concomitant b
-adrenergic blocker administration.222
Although previous studies had suggested that local reactions
were not predictive of systemic reactions, a recent retrospective
study reported that patients who have systemic reactions had an
78. Diagnosis of IgE-mediated reactions to non– beta lac-
tam antibiotics is limited by a lack of knowledge of the
relevant allergenic determinants and/or metabolites. C
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reactions.218 This study indicated that patients with repeated large
local reactions may be at increased risk for AIT- induced anaphy-
laxis.However, this issue remains controversial.227
AIT injections should be administered by health care profes-
sionals trained in the recognition and treatment of anaphylaxis.
AIT should be administered only in health care facilities with
proper equipment for the treatment of anaphylaxis including
epinephrine, oxygen, oral airway, and equipment for the admin-
istration of intravenous fluids and medications.222 AIT should be
administered in a setting with policies and procedures that mini-
mize the risk of anaphylaxis. These policies and procedures should
reduce the risk of dosing errors, ensure proper training of person-
nel, and facilitate treatment of anaphylaxis.222 Most systemic reac-
tions occur within 30 minutes after an AIT injection,220 although
late reactions do occur.214,228 To better recognize and treat ana-
phylactic reactions, patients should wait after receiving an AIT
injection for 30 minutes at the location of the AIT injection.222
In addition, patients at increased risk of systemic reactions, partic-
ularly if they have a history of reactions beginning longer than 30
minutes after an injection, might need to be provided with autoin-
jectable epinephrine, and instructed in its use.214,222 Some patients
may need to remain at the location where the AIT injection was
given for more than 30 minutes after an injection.
ANAPHYLAXIS TO DRUGS AND BIOLOGICAL
AGENTS
Summary Statements
69. Low-molecular-weight medications induce an IgE-
mediated reaction only after combining with a carrier
protein to produce a complete multivalent antigen. B
70. Penicillin is the most common cause of drug-induced
anaphylaxis. C
71. Penicillin spontaneously degrades to major and minor
antigenic determinants, both of which should be in-
cluded in skin testing for penicillin hypersensitivity. B
72. The negative predictive value of penicillin skin testing
with both major and minor determinants (for
immediate-type reactions) is between 97% and 99%
(depending on the reagents used), and the positive pre-
dictive value is at least 50%. B
73. The degree of cross-reactivity between penicillin and
cephalosporins appears to be low. C
74. The degree of cross-reactivity between penicillin and
cephalosporins or carbapenems appears to be low. C
75. Patients with a history of penicillin allergy who have
negative penicillin skin test responses can safely receive
cephalosporins. B
76. Patients who need to receive cephalosporins and who
have a history of penicillin allergy and positive penicil-
lin skin test responses can (1) receive an alternate (non–
beta lactam) antibiotic; (2) receive a cephalosporin
through graded challenge; or (3) receive a cephalospo-
rin through rapid desensitization. C
77. Aztreonam does not cross-react with other beta lac-
tams, except ceftazidime, with which it shares a com-
mon R-group side chain. B79. Aspirin and nonsteroidal anti-inflammatory drugs are
the second most common cause of drug-induced ana-
phylaxis. C
80. Anaphylactic reactions to aspirin and other nonsteroi-
dal anti-inflammatory drugs appear to be medication
specific. D 81. Anaphylactic reactions to omalizumab
have occurred, and post-marketing data indicate that
there is an incidence of approximately 0.2% in treated
patients. These reactions have been unusual in that they
can be delayed in onset and progressive. C
82. Based on the fact that anaphylactic reactions to omali-
zumab can be delayed, an observation period of two
hours for the first three injections, and 30 minutes
thereafter for subsequent injections is indicated. D
83. All patients receiving omalizumab should be prescribed
an automatic epinephrine injector and instructed in its
use. The physician should ensure that the patient has
such an injector with them, at the time of the visits to
the office for injection. D
84. A pre-assessment (before the injection of omalizumab)
of the patient’s current health status should be made.
This should include vital signs, an assessment of asthma
control, and measurement of lung function. D
Medications are the second most common overall cause of
anaphylaxis, and the primary cause of anaphylaxis in adults. The
most common classes of drugs producing anaphylaxis are: 1)
antibiotics, especially ß-lactam antibiotics, and 2) nonsteroidal
antiinflammatory drugs.
Unfortunately there are not adequate skin tests for demonstrat-
ing IgE-mediated (allergic/anaphylactic) potential to most drugs.
Therefore, in most instances, the diagnosis of drug hypersensi-
tivity is based on history and/or challenge.
BETA LACTAM ANTIBIOTICS
If the patient is skin tested with the penicillin product itself, a
minor determinate mixture, and the major determinant (penicil-
loyl polylysine), there is a positive predictive value of 50% or
greater.219, 229 Patients with a positive penicillin skin test response
should receive an alternative antibiotic or undergo desensitization
if penicillin is mandated. Skin testing with penicillin G
and penicilloyl-polylysine, has a negative predictive value of
97% which increases to 99% if a minor determinant mixture is
used .229-231 Patients with negative skin tests to the major and mi-
nor determinants of penicilllin can be safely treated with penicil-
lin. Penicillin skin testing might sensitize a very small proportion
of patients.232
Penicillin and cephalosporins share a common beta lactam
ring, but the extent of allergic cross-reactivity between the two
families appears to be relatively low. Some studies have demon-
strated no serious allergic reactions in large groups of patients
with a history of penicillin allergy who were treated with
cephalosporins.233-235 However, patients in these retrospective
studies were diagnosed with penicillin allergy on the basis of
the history alone and, history is known to be poor predictor of
true penicillin allergy. About 90% of patients with a history of
penicillin allergy are able to receive penicillin without reac-
tion.219, 230 Only a small percentage of patients with a history
of penicillin allergy and a positive penicillin skin test experience
an allergic reaction on being challenged with cephalosporins236.
Nevertheless, fatalities have occurred when patients with a his-
ANTICANCER CHEMOTHERAPY DRUGS
Anaphylaxis to anticancer chemotherapy drugs is being en-
countered more frequently because use of these drugs has
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given cephalosporins.237 There are also case reports from the
1970s of cephalosporin-induced anaphylactic reactions in pa-
tients with a history of penicillin allergy,238,239 but these patients
did not undergo penicillin skin testing, and early cephalosporins
were known to contain trace amounts of penicillin.
Patients with a history of penicillin allergy who have negative
penicillin skin tests are at no higher risk of experiencing allergic
reactionswhengivencephalosporins than thegeneral population239.
If the patient has a history of penicillin allergy and a positive peni-
cillin skin test, and needs to receive cephalosporin, the physician
has threeoptions: (1) administrationofanalternate non–beta lactam
antibiotic; (2) administration of a cephalosporin through graded
challenge; or (3) desensitization to the cephalosporin.239
Aztreonam (Monobactam) does not-cross react with penicillin
or other beta-lactams, aside from ceftazidime, with which it
shares an identical R-group side chain.240 Therefore patients al-
lergic to penicillin and other beta-lactams (except for ceftazi-
dime) can usually safely receive aztreonam. Similarly, patients
allergic to aztreonam can safely receive other beta-lactams, ex-
cept for ceftazidime.
The extent of clinical cross-reactivity between carbapenems
and other beta-lactams appears to be very low, despite an initial
report to the contrary.83 Among penicillin skin test-positive
patients, 111/112 were skin test-negative to imipenem and all
111 tolerated challenge with imipenem.241 Similar tolerability
was seen with meropenem in this same group of individuals.242
Penicillin skin test-negative patients may safely receive carbape-
nems. Penicillin skin test-positive patients and patients with a his-
tory of penicillin allergy who do not undergo skin testing should
receive carbapenems via graded challenge.
Non–beta-lactam antibiotics appear to be uncommon causes of
anaphylactic reactions. Diagnosis of IgE-mediated allergy to
these drugs is more difficult because of the lack of knowledge
about relevant metabolites and allergenic determinants. Skin
testing with the native antibiotic can yield some useful informa-
tion. If a nonirritating concentration is used, a positive result
suggests the presence of drug-specific IgE antibodies.243
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
(NSAIDS)
Aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDs), including COX-2–specific inhibitors, have been
reported to produce anaphylactic reactions. Aspirin and NSAIDs
are the second most common cause of drug-induced anaphylaxis
(after antibiotics).244 Anaphylactic reactions to NSAIDs are unre-
lated to other reactions caused by these drugs, such as respiratory
reactions and exacerbations of chronic idiopathic urticaria.245 Al-
though respiratory and urticarial reactions are often referred to as
anaphylactic, efforts to detect drug-specific IgE antibodies
(through skin testing or in vitro testing) have generally been un-
successful in patients who experience these reactions. True ana-
phylactic reactions to NSAIDs appear to be medication-specific
in that some patients who have had an anaphylactic reaction to
one NSAID are able to tolerate structurally unrelated NSAIDs,
but this is largely based on clinical experience rather than large-
scale challenge studies.244increased,246 particularly the platinum-containing drugs, such
as cisplatinum and carboplatinum. Skin testing to these agents
may be helpful in determining whether sensitivity exists and at
what dose to proceed with desensitization if this is necessary.247
In addition, acute anaphylactoid infusion reactions occur in up
to 42% of patients treated on first exposure 248 for which rapid de-
sensitization is possible.249,250 In some instances the solvent in
which these drugs are formulated (Cremophor-L) might cause
an anaphylactic reaction251. Components other than the drug pro-
duct itself may be the cause of significant reactions with other
drugs, such as heparin.252
BIOLOGICAL MODIFIERS AND MONOCLONAL
ANTIBODIES
Anaphylaxis to biological modifiers and monoclonal anti-
bodies has been known to occur.253 Most notably, there has been
concern regarding anaphylactic events that occurred after admin-
istration of omalizumab (anti-IgE). In this regard, one hundred
twenty-four cases of anaphylaxis were reviewed by the Food
andDrugAdministration.254 A significant percent of anaphylactic
reactions to omalizumab were delayed in onset and exhibited a
protracted progression of symptoms. Some cases required hospi-
talization. No potential factors were noted that identified patients
at risk for such reactions.
The analysis of the post-marketing for omalizumab indicated
that the overall frequency of anaphylaxis is approximately 0.09%
to 0.2% of treated patients; a frequency higher than reported in the
pre-marketing clinical trials database. With these observations in
mind, the omalizumab Joint Task Force of the American Acad-
emy of Allergy, Asthma, and Immunology and the American
College of Allergy, Asthma, and Immunology issued guidelines
regarding the precautions necessary when administering
omalizumab.255
The Task Force recommended that: 1) patients should be
observed for two hours after the first three injections of
omalizumab, and for 30 minutes after subsequent injections; 2)
omalizumab should not be administered at home or in a facility
that does not have appropriate staff and equipment to treat
anaphylaxis; 3) informed consent should be obtained after
discussing the risks, benefits, and alternatives to treatment with
omalizumab; 4) patients receiving omalizumab should be trained
in the recognition of the signs and symptoms of anaphylaxis, and
in the use of an epinephrine auto-injector; 5) patients should be
advised to have this auto-injector available during and following
the administration of omalizumab; 6) the physician should ensure
that patients have their injector and have been instructed in its use;
and 7) an assessment of patients prior to the administration of
omalizumab should be made, including vital signs, an assessment
of asthma control, and a measurement of lung function.
Cetuximab, a chimeric mouse/human IgG1 monoclonal
antibody to epidermal growth factor receptor used in the treat-
ment of colorectal cancer and squamous cell cancer of the head
and neck has been associated with anaphylactic reactions.256
A desensitization protocol has been developed for Cetuximab.257
Anaphylaxis occurs because IgE antibodies develop to galactose
alpha1, 3 galactose present on the Fab portion of the Cetuximab
heavy-chain. IgE antibodies have also been demonstrated to this
galactose carbohydrate epitope in meat, which might account for
reactions that occur during the first dose.258
regimen fails to prevent what appears to be an anaphylactoid
reaction. noncardiogenic pulmonary edema, in particular, should
be considered.268 RCM can also expand intravascular volume and
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Summary StatementsRadiographic contrast material (RCM) is used in more than 10
million radiologic examinations annually in the United States.
The overall frequency of adverse reactions (including anaphy-
lactoid and nonanaphylactoid reactions) is 5% to 8%. Moderate
reactions, such as severe vomiting, diffuse urticaria, or angioe-
dema, that require therapy occur in about 1% of patients who
receive RCM. However life-threatening reactions occur with a
frequency of less than 0.1% with conventional high-osmolality
RCM.259,260 Although studies quote awide spectrum ofmortality,
a reasonable estimate is one in every 75,000 patients who receive
RCM.261With the recent development of lower-osmolality RCM,
it appears that the overall risk of anaphylactoid reactions has de-
creased to about one fifth that of conventional RCM.262
The prevalence of adverse reactions to RCM appears to be
greatest in patients 20 to 50 years of age. When adverse reactions
occur, however, they are usually most severe in elderly patients.
Patients who are at greatest risk for an anaphylactoid reaction
to RCMare thosewho have experienced a previous anaphylactoid
reaction to RCM. This risk has been reported to be between 16-
44%.263,264 Even, without a history of a previous anaphylactoid
reaction, patients with atopy, asthma, or cardiovascular disease
are recognized to be at increased risk of developing such a reac-
tion.265-267 There is no evidence that the inorganic iodine levels
present in seafood or in topically applied iodine-containing solu-
tions are related to adverse events from RCM.
Anaphylactoid reactions have occurred when RCM is used for
hysterosalpingograms,myelograms, and retrograde pyelograms.263
With the use of a pretreatment protocol and the use of lower-
osmolarity agents, the risk can be reduced to approximately 1%.268
Anaphylactoid reactions to RCM are independent of the dosage
or concentration of RCM administered. Clinically, these reactions
are identical to immediate hypersensitivity IgE-mediated reac-
tions (anaphylaxis) but do not appear to involve IgE or any other
immunologic mechanism.266
Pretreatment regimens for prevention of repeat anaphylactoid
reactions have consisted of oral glucocorticosteroids, H1 and H2
antihistamines, and other medications, such as ephedrine.
A regimen that has been commonly recommended in the past
has been 50 mg of prednisone given orally 13, 7, and 1 hours
before administration of RCM; 50 mg of diphenhydramine given
orally or intramuscularly 1 hour before the administration of
RCM; and 25 mg of ephedrine given orally 1 hour before RCM
administration.Modifications to this regimen have included lower
doses of glucocorticosteroids, oral rather than intramuscular
diphenhydramine, the use of other H1 antihistamines, addition
of H2 antihistamines, and/or exclusion of ephedrine. If the patient
has to undergo an emergency radiographic procedure, an emer-
gency pretreatment protocol that has been used successfully
consists of 200 mg of hydrocortisone administered intravenously
immediately and every 4 hours until the RCM is administered,
and 50 mg of diphenhydramine administered intramuscularly
1 hour before RCM.267
In a setting in which RCM is being administered, a differential
diagnosis might include adult respiratory distress syndrome or
noncardiogenic pulmonary edema. If a standard pretreatmentprecipitate cardiogenic pulmonary edema in patients with ische-
mic cardiac disease.
STINGING INSECT HYPERSENSITIVITY85. Anaphylaxis to insect stings has occurred in 3% of
adults and 1% of children who have been stung, and
can be fatal even on the first reaction. B
86. Cutaneous systemic reactions are most common in chil-
dren, hypotensive shock is most common in adults, and
respiratory manifestations occur equally in all age
groups. B
87. The chance of a systemic reaction to a sting is low
(5-10%) in patients who have large local reactions and
in children with mild (cutaneous) systemic reactions. A
88. Venom skin tests are most sensitive for diagnosis but in
vitro testing is an important complementary test. A
89. The degree of sensitivity on skin or in vitro tests does not
reliably predict the severity of a sting reaction. B
90. Since asymptomatic venom sensitization can be de-
tected in up to 25% of adults, diagnosis cannot be
made on skin testing alone; the history is essential. C
91. Patients discharged from emergency care of anaphy-
laxis should be given or prescribed auto-injectable epi-
nephrine and receive instruction in its proper use and
indications for use as well as advised to set-up an ap-
pointment with an allergist-immunologist. Patients
should understand, however, that using auto-
injectable epinephrine is not a substitute for emergency
medical attention. A
92. Venom immunotherapy (VIT) should be recommended
for patients with systemic sensitivity to stinging insects
as this treatment is highly (90% to 98%) effective. B
93. Most patients can discontinue VIT after 5 years, with
low residual risk of a severe sting reaction. A
94. There is a need to develop tests that are: 1)markers of
susceptibility that can serve as a screening test to iden-
tify patients at high risk of sting anaphylaxis; and 2)
markers of tolerance induction to identify patients
who can safely discontinue venom immunotherapy. D
Stinging insects of the order Hymenoptera can cause systemic
allergic reactions211,269-278 including anaphylaxis, but biting in-
sects rarely cause such reactions. Large local sting reactions
can cause delayed and prolonged local inflammation increasing
over 24 to 48 hours and resolving in 3 to 10 days. These reactions
are IgE-mediated, but carry a relatively low risk of anaphylaxis
from future stings.211 Systemic (generalized) reactions may in-
clude any one or more of the signs and symptoms of anaphy-
laxis.279,282-286 Systemic reactions involving only cutaneous
manifestations do not strictly fit the definition of anaphylaxis
but are discussed here because they must be considered in the
diagnosis and treatment of stinging insect allergy, as potential
precursors of anaphylactic reactions.279 Anaphylaxis due to an in-
sect sting differs clinically between children and adults. Cutane-
ous symptoms and signs are the sole manifestation in only 15% of
adults but in more than 60% of children.285 Almost 50% of
reactions in both children and adults include respiratory manifes-
tations. Symptoms and signs of hypotension are uncommon in
children but occur in over 60% of adults, with half experiencing
testing, but may be useful when skin tests cannot be done or when
skin tests are negative in a patient with a history of a systemic
reaction(2712).
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Three families of the order Hymenoptera can cause anaphy-
laxis: the bees (honeybees, bumblebees), vespids (yellow jackets,
hornets, wasps), and stinging ants (genus Solenopsis). There have
been increasing reports of anaphylaxis due to other species of
stinging ants in Asia and Australia.287 The immunochemical char-
acteristics and immunogenetic relationships of the Hymenoptera
venoms have been thoroughly studied.288,289 Honeybee venom is
immunochemically distinct from the other Hymenoptera, but ves-
pid venoms have a high degree of cross reactivity with each other.
The proteins in fire ant venoms are antigenically unique. Fire ant
whole body extract, unlike the other Hymenoptera whole body ex-
tracts, does show reasonable allergenic activity for diagnostic skin
testing and for preventative immunotherapy.289
Systemic allergic reactions to insect stings are reported by up to
3% of adults, and almost 1% of children who have been
stung.290,291 At least 50 fatal reactions to an insect sting occur
each year in the United States. Half of these occur in individuals
who had no history of a previous reaction to an insect sting.283
Screening for clinically significant hymenoptera sensitivity is
complicated by the fact that over 30% of adults stung in the pre-
vious 3 months have venom-specific IgE by skin or in vitro testing
even though most had no history of an allergic reaction to an in-
sect sting.290 Although many of these individuals became nega-
tive for venom-specific IgE after 3-6 years, those who remained
positive had a 17% frequency of a systemic reaction to a subse-
quent sting.292
Systemic reactions can become progressively more severewith
each sting, but this is the exception rather than the rule. In
prospective sting challenge studies, less than 1% of the patients
had a reaction more severe than their previous reaction,293,294 al-
though in retrospective surveys more severe reactions were noted
in a larger percent of patients.284,295
Clinical features of anaphylaxis from an insect sting are
identical to those due to other causes of anaphylaxis. If the
patient experiences a large local reaction to an insect sting, in the
absence of a systemic response, venom immunotherapy (VIT) is
not usually necessary, although patients with large local reactions
are at increased risk for a systemic reaction (5 to 10%).296 In chil-
dren, a systemic reaction consisting of urticaria alone does not
always mandate VIT, although such reactions may be potential
precursors of an anaphylactic reaction with subsequent stings. Pa-
tients with severe reactions to insect stings should be evaluated for
the presence of systemic mast cell disease.211
Diagnostic tests are indicated in patients who have had
systemic reactions to insect stings.297,298 The preferred diagnostic
method is venom skin testing because of its high degree of sensi-
tivity and proven safety.271 Skin test results are positive in 65-85%
of patients with a convincing history. Venom skin tests also show
unexplained variability over time so that tests can be negative on
one occasion and positive on another.299
A negative skin test in a history-positive patient can be due to
loss of sensitivity over time. In addition, there is a refractory
period of several weeks after an insect sting reaction, during
which a false negative skin test may occur. In this situation, skin
tests may have to be repeated after one to six months.269 The de-
gree of skin test sensitivity does not correlate reliably with the se-
verity of a sting reaction. In vitro testing is less sensitive than skinSome investigators have suggested that sting challenge is the
most specific diagnostic test, but others find this unethical and
impractical.294,300,301 Furthermore, a single negative challenge
sting does not preclude anaphylaxis to a subsequent sting .293,302
Toxic reactions due to massive envenomation from multiple
stings estimated to be greater than 100,254 might be clinically in-
distinguishable from allergic reactions since mediators can pro-
duce physiologic effects which mimic those produced from an
allergic reaction.
Individuals who are allergic to stinging insects should avoid
areas with a high risk of exposure, particularly outdoor settings
with foods and drinks that may attract stinging insects. However,
excessive fear can impair a patient’s quality of life and needs to be
included in the considerations for venom immunotherapy.280
Auto-injectible epinephrine should be provided to any patient
who has experienced a systemic reaction to an insect sting, with
the exception of children who have experienced only a cutaneous
reaction.
In placebo-controlled trials venom immunotherapy (VIT) was
90-98% effective in completely preventing systemic reactions to
stings.272-274 The indications for VIT are a history of a systemic
allergic reaction to a sting and a positive diagnostic test for
venom-specific IgE. Those with a recent history of anaphylaxis
from an insect sting and a positive skin test have a 30% to 70%
chance of a systemic reaction to a subsequent sting.273,294,303
VIT is not required when the chance of a systemic reaction is
<10%, as in large local reactors and children with cutaneous sys-
temic reactions, but still may be considered in this setting.304-307
Therapy is 98% effective in completely preventing a systemic
allergic reaction to a sting when treatment includes mixed vespid
venoms (300 mcg total dose), but complete protection is achieved
in only 75% to 85% of patients utilizing 100 mcg of any single
venom (e.g., honeybee, yellow jacket or Polistes wasp).275-277
Fire ant immunotherapy using whole body extracts has been re-
ported to be reasonably safe and effective, although no controlled
studies have been performed. Fire ant venoms are not available
for diagnosis or treatment, but there has been a very successful
controlled trial of immunotherapy with Jack Jumper ant venom
in Australia.308
Protection from sting anaphylaxis with rapid venom immuno-
therapy can be achieved in days or weeks, and adverse reactions
are no more common than with regular inhalant therapy.274,275
Immunotherapy with whole body extract of fire ant has been
shown to be safe and effective for treatment of patients who have
had a systemic reaction to a fire ant sting, although there have
been no controlled trials demonstrating safety and efficacy.276,277
See updated parameter on stinging insect hypersensitivity.
In a retrospective study of patients experiencing anaphylaxis
from hymenoptera venom,309 ACE inhibitor exposurewas associ-
ated with statistically significant increase in risk for more severe
anaphylaxis (OR5 2.27, 95%CI5 1.13-4.56, p5 .019). AsACE
inhibitors are frequently prescribed for patients with cardiovascu-
lar disease, a tenable interpretation of these data is that ACE in-
hibitor exposure is a marker for patients with more severe
cardiovascular disease. On the other hand, as ACE inhibitors
may indeed enhance risk for more severe anaphylaxis, based on
these data and previously published case reports,310 it is prudent
to consider ACE inhibitor suspension to reduce risk for untoward
outcomes in patients with anaphylactic potential to hymenoptera
venom and/or receiving venom immunotherapy, while supplant-
ing the ACE inhibitor with an eqully efficacious non ACE inhib-
risk factors for anaphylaxis include, but are not limited to: a prior
history of such reactions; patient exposure to the possible
trigger(s); and atopic background. An atopic background may
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inhibitor for an indication for which there is no equally effective
alternative available, a management decision by the physician
prescribing venom immunotherapy should be approached cau-
tiously on an individualized risk-benefit basis.
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ing into consideration factors such as age, activity, occu-
pation, hobbies, residential conditions, access to medical
care, and the patients’ level of personal anxiety. C
96. Even in cases when the allergen is known, avoidance
measures may not always be successful. Therefore, pa-
tients should be instructed in self-management of ana-
phylaxis. C
97. Venom immunotherapy (VIT) is successful in prevent-
ing anaphylaxis in up to 98% of patients who have pre-
viously experienced venom-induced anaphylaxis. A
98. Pharmacologic prophylaxis should be used in select sit-
uations, e.g. to prevent recurrent anaphylactic reac-
tions to radiographic contrast material and
fluorescein, as well as to prevent idiopathic anaphy-
laxis. In these specific situations, prophylaxis with glu-
cocorticosteroids and antihistamines markedly
reduces the occurrence of subsequent reactions. C
99. Desensitization to medications that are known to have
caused anaphylaxis can be effective. The desensitization
is temporary, and if the medication is required in the fu-
ture, the desensitization process must be repeated. C
100. Patient education might be the most important pre-
ventive strategy. Education can emphasize hidden al-
lergens, cross- reactivity between various allergens
and drugs, unforeseen risks during medical proce-
dures, and when and how to use self-administered ep-
inephrine. Physicians should educate patients about
the risks of future anaphylaxis, as well as the benefits
of avoidance measures. B
Patients should be educated regarding avoidance measures for
known or suspected triggers of anaphylaxis. This should take into
consideration factors such as age, concomitant conditions, activ-
ity, occupation, hobbies, residential conditions, access to medical
care, as well as and the patient’s level of personal anxiety.
Education should emphasize hidden allergens, cross-reactivity
between various allergens and drugs, and unforeseen risks during
medical procedures.
Patients discharged from emergency care of anaphylaxis
should receive instruction on prevention of future episodes and
when and how to administer auto-injectible epinephrine, with an
understanding that these measures are not a substitute for
emergency medical attention during anaphylaxis.311 Following
emergency treatment, the patient should be seen in consultation
by an allergist/immunologist to review potential causes, preven-
tion, and treatment of subsequent episodes.
Awareness of the risk factors for anaphylaxis is important in
preventing the occurance of such reactions. Recognition of majorbe a risk factor for stinging insect and latex-induced anaphylaxis
(and possibly anaphylactoid reactions to radiographic contrast
material) but not for anaphylactic reactions to medications. This
is particularly important in regard to avoidance by the patient of
possible triggers. Avoidance measures can be successful in any
given patient if future exposure to allergens which have been
shown to produce anaphylaxis in that patient can be prevented.
However, avoidance measures must be individualized, taking into
consideration patient age, activity, occupation, hobbies, residen-
tial conditions, access to medical care, and the patients’ level of
personal anxiety.
Patients who will be exposed to known triggers of a prior
reaction can in some cases be protected by: 1) pharmacologic
prophylaxis; 2) allergen immunotherapy; or 3) desensitization.
Pharmacologic prophylaxis can be used to prevent recurrent
anaphylactic/anaphylactoid reactions to radiographic contrast
material and fluorescein, as well as idiopathic anaphylaxis.
Physicians should educate patients about the risks of future
anaphylaxis, as well as the benefits of avoidance measures. The
prevention of anaphylaxis is aided by the patients having medic
alert identification.
At times, a preventative protocol may be of benefit. For
example, a pretreatment regimen has been successfully employed
to prevent reactions to radiocontrast material in patients who have
previously reacted to this diagnostic agent.
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FIG E1. Algorithm for initial evaluation andmanagement of a patient with a history of a previous episode of
anaphylaxis.
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FIG E2. Algorithm for the treatment of an anaphylactic event in the outpatient setting. IV, Intravenous.
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FIG E3. Suggested anaphylaxis supply check sheet. BP, Blood pressure; IV, intravenous.
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FIG E4. Anaphylaxis treatment record. BP, Blood pressure; rxn, reaction; Hx, history; EMS, Emergency
Medical Services; Resp, respirations; PEFR, peak expiratory flow rate.
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TABLE E1. Frequency of occurrence of signs and symptoms of
anaphylaxis*yz
Signs and Symptoms Percent
Cutaneous
Urticaria and angioedema 85-90
Flushing 45-55
Pruritus without rash 2-5
Respiratory
Dyspnea, wheeze 45-50
Upper airway angioedema 50-60
Rhinitis 15-20
Dizziness, syncope, hypotension 30-35
Abdominal
Nausea, vomiting, diarrhea, cramping pain 25-30
Miscellaneous
Headache 5-8
Substernal pain 4-6
Seizure 1-2
*On the basis of a compilation of 1865 patients reported in references.1 through 14
Percentages are approximations.
Children may have a lower frequency of cutaneous symptoms in anaphylaxis.
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TABLE E2. Differential diagnosis of anaphylaxis
Reactions caused by the excess endogenous production of histamine
Systemic mastocytosis
Urticaria pigmentosa
Basophilic leukemia
Acute promyelocytic leukemia with retinoic acid treatment
Hydatid cyst
Vasodepressor (vasovagal) reactions
Other forms of shock
Hemorrhagic
Hypoglycemic
Cardiogenic
Endotoxic
Flushing disorders
Rosacea
Carcinoid
Red man syndrome as a result of vancomycin
Postmenopausal
Alcohol-induced
Unrelated to drug ingestion
Related to drug ingestion
Medullary carcinoma thyroid
Autonomic epilepsy
Vasointestinal peptide and other vasoactive peptide–secreting
gastrointestinal tumors
Ingestant-related reactions mimicking anaphylaxis (restaurant syndromes)
Monosodium glutamate
Sulfites
Scombroidosis
Miscellaneous
C1 esterase deficiency syndromes (acquired and hereditary angioedema)
Pheochromocytoma
Neurologic (seizure, stroke)
Capillary leak syndrome
Panic attacks
Vocal cord dysfunction syndrome
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TABLE E3. Laboratory tests to be considered in the differential diagnosis of anaphylaxis
To be measured Comment
Serum tryptase Serum tryptase levels peak 60-90 min after the onset of anaphylaxis and persist to 6 h.
Ideally the measurement should be obtained between 1 and 2 h after the initiation of
symptoms.
Plasma histamine Plasma histamine levels begin to rise within 5-10 min and remain elevated only for 30-60
min. They are of little help if the patient is seen as long as an hour or more after the
onset of the event.
24-Hour urinary histamine metabolite
(methyl histamine) of time
Urinary histamine and its metabolites are elevated for a longer period
– up to 24 h.
Plasma-free metanephrine To rule out a paradoxical response to a pheochromocytoma.
Urinary vanillylmandelic acid Also useful in ruling out a paradoxical response to a pheochromocytoma.
Serum serotonin To rule out carcinoid syndrome.
Urinary 5-hydroxyindoleacetic acid Also to rule out carcinoid syndrome.
Serum vasointestinal hormonal polypeptide panel including
pancreastatin, pancreatic hormone, Vasointestinal
Polypeptide, and substance P
Useful to rule out the presence of a vasoactive polypeptide–secreting gastrointestinal
tumor or a medullary carcinoma of the thyroid, which also can secrete vasoactive
peptides.
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TABLE E4. Special considerations for anaphylaxis in children
I. When is it hypotension?
Age Systolic blood pressure (mm Hg)
Term neonates (0-28 d) <60
Infants (1-12 mo) <70
Children (>1 y to 10 y) <70 1 (2 3 age in y)
Beyond 10 y <90
II. Infusion rates for epinephrine and dopamine in children with cardiac arrest or profound hypotension
Medication Dose range Preparation*
Dopamine 2-20 mg/kg/min 6 3 body weight (in kg) 5 # of mg diluted to total 100 mL saline; then 1 mL/h delivers 1 mg/kg/min
Epinephrine 0.1 mg/kg/min 0.6 3 body weight (in kg) 5 # of mg diluted to total 100 mL saline; then 1 mL/h delivers 0.1 mg/kg/min
*Infusion rates shown use the ‘‘rule of 6.’’ An alternative is to prepare a more dilute or more concentrated drug solution based on a standard drug concentration, in which case an
individual dose must be calculated for each patient and each infusion rate, as follows: infusion rate (mL/h)5 (weight [kg]3 dose [mg/kg/min]3 60 min/h)/concentration (mg/mL).
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TABLE E5. Latex-containing articles potentially used for anes-
thesia or surgery
Adhesive tape
Airway masks
Ambu-bag
Anesthesia bags and tubing
Self-adhesive bandages
Blood pressure cuffs
Bulb syringes
Catheter leg bag straps
Catheters
Condoms
Indwelling
Straight
Elastic bandages
Electrode pads
Endotracheal tubes
Gloves, sterile and exam
Intravenous bags, ports, infusion sets
Penrose drains
Rubber pads
Stethoscope tubing
Suction catheters
Syringes
Tourniquets
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TABLE E6. Example of contents of latex-free cart
I. Glass syringes
II. Ampules
III. Tubing without ports (taped ports)
IV. Stopcocks
V. Nonlatex stethoscope
VI. Nonlatex gloves
VII. Nonlatex breathing system
Neoprene bags
Plastic masks
Nonlatex Ambu
Uncuffed polyvinyl chloride endotracheal tube
VIII. Dermicel
IX. Disposable nonlatex blood pressure cuffs
X. Webril tourniquets
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TABLE E7. Agents frequently implicated in perioperative anaphylaxis and probable mechanisms of adverse reactions
Agent IgE-mediated mast cell activation Complement-mediated Direct mast cell activation
Muscle relaxants
d-TubocurarineSuxamethonium (succinylcholine)
Pancuronium
Atracurium
Vecuronium
1 2 1
Hypnotics-barbiturates
Thiopental
Methohexitone
1 1 1
Nonbarbiturate hypnotics
Propofol
Althesin
6 1 1
Opioids
Morphine
Buprenorphine
Fentanyl
6 2 1
Plasma expanders
Dextran
Hydroxyethyl starch
2 1 1
Protamine 1 1 1
Radiocontrast media 2 1 1
Latex 1 2 2
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TABLE E8. Skin testing concentrations for anesthetic agents
Medication
Intradermal skin
test concentration (mg/mL)
Alcuronium 0.005
Methohexital 0.1*
Metocurine 0.002*
Pancuronium 0.002*
Succinylcholine 0.02,* 0.05
Thioamyl 0.1*
Thiopental 0.20*
Tubocurarine 0.0003,* 0.001
Rocuronium 0.01
Vecuronium 0.004
*Rose and Fisher (2001)123
Moscicki et al (1990)122
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